

27th Pharmaceutical and Medical Device Ethics and Compliance Congress


October 13 – 16, 2026

Washington Hilton • Washington, DC



A Hybrid Event — Onsite or Virtual Online Event Live and Archived

All Times are EDT • Agenda Current as of September 12, 2026 • Subject to Change and Regular Updates



Sponsored
by the
Pharmaceutical
Compliance
Forum (PCF)

C-SUITE CONGRESS VIDEO WELCOME:

GOVERNMENT KEYNOTE SPEAKERS:



Albert Bourla, DVM, PhD, *Chairman and Chief Executive Officer, Pfizer; Former Chair, Pharmaceutical Research and Manufacturers of America (PhRMA); Former President, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)*



Jacob Foster, JD, *Acting Chief, Health Care Fraud Unit, Criminal Division, Fraud Section, US DOJ*



Brenna Jenny, JD, MPH, *Deputy Assistant Attorney General, Commercial Litigation Branch, Civil Division, US DOJ*



Mary E. Riordan, JD, *Senior Counsel to the Inspector General, HHS Inspector General*



Veronika Peleshchuk Fradlin, MPP, *Director, Transparency & Data Group, Centers for Medicare & Medicaid Services, US HHS*



Twyla Mosey, PharmD, RPh, *Director, Office of Prescription Drug Promotion, US FDA*

PCF BOARD:



Donna White, CCEP, *Vice President and Compliance Officer, Chiesi Farmaceutici S.p.A., Americas Region (Board Chair)*



Jill Dailey, JD, *Vice President & Chief Compliance Officer, Oncology, Menarini Stemline*



Daryl Kreml, JD, *Vice President, Head of Ethics & Compliance, Global Oncology, Takeda*



Christie Camelio, *Senior Vice President and Chief Compliance Officer, Inmed*



Anisa Dhalla, *Vice President, Global Head, Ethics and Business Integrity, UCB*



Melissa T. Lozner, JD, *Senior Vice President, Chief Compliance Officer, Regeneron*

MEDICAL DEVICE EXECUTIVE STEERING COMMITTEE:



Sujata Dayal, JD, LLM, *Founder & Senior Advisor, Arziyan LLC; Independent Board Director, Emergent BioSolutions*



Mona Peterson Rosow, JD, MPH, *Former Vice President, Chief Risk, Ethics & Compliance Officer, Mozarc Medical*



Daniel Spicehandler, JD, *Vice President Compliance, Commercial Divisions, Stryker*



JJ Kuhn, JD, *Chief Ethics & Compliance Officer, DanaHER*



Tara Shewchuk, JD, LLM, *Senior Vice President, Chief Privacy, Integrity & Compliance Officer, Medtronic*

TABLE OF CONTENTS

Grantors	page 3
Agenda-at-a-Glance	page 4
Detailed Agenda	page 8
CCO Roundtable (Invitation-only)	page 18
Industry-Only Day	page 26

AN OVERVIEW OF THE 27TH CONGRESS SCHEDULE

Day 1: Tuesday, October 13, 2026

- Afternoon Half-day Specialty Focused Sessions

Day 2: Wednesday, October 14, 2026

- Networking Breakfast in Exhibit Hall
- Morning Concurrent Mini Summits
- Networking Luncheon in Exhibit Hall
- Afternoon Opening Plenary Session
- Networking Reception

Day 3: Thursday, October 15, 2026

- Networking Breakfast in Exhibit Hall
- Morning PCF CCO Roundtable (Invitation-only, Breakfast Included)
- Morning Concurrent Mini Summits
- Networking Luncheon in Exhibit Hall
- Afternoon Closing Plenary Session

Day 4: Friday, October 16, 2026

- Networking Breakfast
- Morning PCF Industry-only Think Tank
- Noon: Congress Adjournment

IMPORTANT THINGS TO REMEMBER AS YOU PREPARE TO ATTEND THE CONGRESS

- For the first time, the Congress is offering 5 half-day Focused Sessions on Hot Topics on Tuesday afternoon, October 13.
- Onsite attendees may register onsite as early as 10 am ET on Tuesday, October 13.
- All onsite attendees will have the ability to scan QR codes on badges to exchange contact information.
- For the first time, all Congress attendees (both onsite and online) will be able to text each other via the Congress App.
- All onsite attendees will also have access to the Congress. Virtual Video/Audio Archive for at least 9 months following the Congress. This will allow attendees to watch sessions that they missed at the Congress.



ABOUT THE CONGRESS SPONSOR, THE PHARMACEUTICAL COMPLIANCE FORUM

Since 1999, PCF has been dedicated to the advancement of the pharmaceutical compliance profession. Our meetings provide a forum for members to share knowledge, explore innovative solutions to complex compliance challenges and network with peers to build long lasting career relationships.

The PCF's Vision is to be the leading forum in the pharmaceutical and biotech industry for promoting excellence in the compliance profession and advance effective and sustainable risk-based compliance programs through solutions-oriented collaboration and innovative best practice sharing.

PCF is proud of its Board, a team of six senior compliance executives who dedicate and volunteer their time to serve, each appointed by the membership for three-year terms. Our leadership team is responsible for setting the organization's strategic direction, overseeing business affairs, and ensuring we deliver meaningful value to our members.

For more information regarding the PCF, please contact PCF Administrator Debra Scanlon at deb_admin@pcf-org.com.



**PCF Administrator
Debra Scanlon (Deb)**

PLATINUM GRANTOR



GOLD GRANTORS




SILVER GRANTORS



COVINGTON



BRONZE GRANTORS



MEDIA PARTNERS



AGENDA AT A GLANCE

DAY 1: TUESDAY, OCTOBER 13, 2026

(Included in standard Congress registration)

11:00 am Registration Opens

1:00 pm – 5:45 pm **IN-DEPTH, HALF-DAY, AFTERNOON FOCUSED SESSIONS** (Included in your Congress registration)

Focused Session 1: **Whistleblower Complaints: From Hotline to Resolution: Managing Internal Investigations, Whistleblower Risk & Escalation Decisions**

- 1:00 pm** • Chair's Welcome and Introductions & DOJ/ FCA Enforcement Trends: Lessons from Whistleblower Cases
- 1:45 pm** • Qui Tam Counsel Roundtable
- 2:30 pm** • With Data and AI, Whistleblowers Set Off an FCA Tidal Wave
- 3:45 pm** • Hotline Isn't Enough: Building a Smart Investigations Ecosystem
- 4:30 pm** • Anatomy of an Internal Investigation
- 5:15 pm** • Managing Whistleblower Risk and Internal Escalation

5:45 pm **Adjournment**

Focused Session 2: **Pharmaceutical and Medical Device Advanced Privacy and Security/Cybersecurity Updates**

- 1:00 pm** • Chair's Welcome, Overview and Introductions
- 1:15 pm** • The Basics of Healthcare Privacy for Compliance Professionals and an Overview of Privacy Issues Unique to Pharmaceutical and Medical Device Enterprises
- 1:45 pm** • IAPP Presents: Privacy, AI Compliance, and Beyond for the Future of Pharma and Medical Devices
- 2:30 pm** • The International Pharmaceutical and Medical Device Privacy Consortium Presents Advanced Strategies for Addressing Privacy and Cybersecurity Issues for Life Sciences Companies
- 3:15 pm** • Companies from the Cybersecurity Working Group, Health Sector Coordinating Council
- 4:15 pm** • Cybersecurity Best Practices for Pharma and Device
- 5:00 pm** • Session Faculty Q&A

5:45 pm **Adjournment**

Focused Session 3: **Managing Medical — Commercial Interactions: Strategic Collaboration, Evolving Roles & Risk-Based Governance**

- 1:00 pm** • Co-Chair's Introductions & Session Overview
- 1:15 pm** • Strategic Planning Together, Tactical Execution Separately: Practical Case Studies in Medical–Commercial Collaboration
- 2:00 pm** • Beyond Sales Representatives and MSLS: Understanding Emerging Field-Based Roles and Governance Challenge
- 3:15 pm** • Protecting Medical Independence While Enabling Strategic Cross-Functional Collaboration
- 4:00 pm** • Medical–Commercial Boundaries: Congresses, Sponsorships & Promotional Risk
- 4:45 pm** • Have We Become Too Restrictive? Rethinking Medical–Commercial Governance for the Next Era

5:30 pm **Adjournment**

Focused Session 4: **AI in Action: Real-World Compliance Case Studies from the Front Lines of AI Use in Life Science Compliance Departments**

- 1:00 pm** • AI Basics, Life Science Industry Ethics and Compliance Applications
- 1:30 pm** • A Brief Overview of the Epsilon Annual AI Use Compliance Survey
- 2:00 pm** • Facilitated Case Study Discussion: From Transcript to Insights: How Compliance Teams Are Using AI to Transform Investigations
- 2:30 pm** • Facilitated Case Study Discussion: AI Governing AI: Leveraging Artificial Intelligence to Develop Effective Governance Policies
- 3:15 pm** • Facilitated Case Study Discussion: AI-Assisted Monitoring and Detection of Potential Policy Violations
- 3:45 pm** • Facilitated Case Study Discussion: Agentic AI Use for Continuous Risk Assessment (vs Annual)
- 4:15 pm** • The Unspoken Risk of AI: Moral Outsourcing — and Why “Add Human Judgment” Isn't Enough
- 5:00 pm** • The Health Care Compliance Association Presents: Advanced Strategies in Using AI to Monitor and Improve Compliance: Lessons from Other Healthcare Sectors

5:45 pm **Adjournment**

Focused Session 5: **GP 101: A Primer on the Fundamentals of Government Pricing for Compliance Officers & The Evolving Pricing and Contracting Landscape: What Compliance Officers Need to Know**

- 1:00 pm** • Chair's Introductions & Session Overview
- 1:15 pm** • GP 101: A Primer on the Fundamentals of Government Pricing for Compliance Officers
- 4:00 pm** • The Evolving Pricing and Contracting Landscape: What Compliance Officers Need to Know

5:30 pm **Adjournment**

AGENDA AT A GLANCE

DAY 2: WEDNESDAY, OCTOBER 14, 2026

7:00 am Registration Opens & Networking Breakfast in Exhibit Hall

8:00 am – 8:50 am MORNING MINI SUMMITS: GROUP 1

MS1: Compliance Independence in the Real World: Governance Models That Work

MS2: The Agentic Compliance Function of the Future

MS3: Evolution of Patient Finding Activities

MS4: First Product Launch: Policy Development Strategies and Techniques

MS5: Speaker Programs in 2026: Practical Legal and Compliance Considerations for Executing from Beginning to End Amid Ongoing Scrutiny

9:00 am – 9:50 am MORNING MINI SUMMITS: GROUP 2

MS6: From Pronouncements to Practice: Understanding DOJ Enforcement Priorities

MS7: Boring is Risky! Want Stronger Ethics and Compliance Engagement? Train & Communicate Colorfully

MS8: Best Practices for Data Analytics

MS9: On the Front Lines: Navigating Field Force & Sales Compliance Risk

MS10: Communicating the Story on Integrity: What Compliance Leaders Can Learn from Health Stakeholders

MS11: Designing HCP Engagement with Transparency Built In

9:50 am – 10:10 am NETWORKING BREAK (in the Exhibit Hall)

10:10 am – 11:00 am MORNING MINI SUMMITS: GROUP 3

MS12: Compliance and M&A: Why Early Engagement Matters

MS13: The State of Medical Device Compliance: Annual Industry Roundtable

MS14: The State We're In: Legal & Enforcement Trends Reshaping Life Science Companies' Compliance

MS15: External Funding Risks and Mitigation: Latest Trends in Exhibit & Display and Sponsorship Requests

MS16: Beyond the Questionnaire: Building a Risk-Based Third-Party Management Program That Actually Works

MS17: Navigating Today's Enforcement Landscape with Culture, Data, and Ethics

11:10 am – 12:00 pm MORNING MINI SUMMITS: GROUP 4

MS18: Risk Advantage: How Resilient Organizations are Capturing Opportunity through Uncertainty

MS 19: View from the Top: Practical Advice for Accelerating Your Compliance Career

MS 20: Direct-to-Consumer (DTC) Models: Emerging Compliance Risks and Governance Considerations

MS 21: Fair Market Value: Practical Strategies and Targeted Insights for Building Defensible FMV Frameworks

MS 22: Navigating the Evolving US Privacy Landscape

MS 23: Agentic Risk Management: Transforming Compliance Across Key Business Processes

12:00 pm – 1:00 pm NETWORKING LUNCHEON — OR — OPTIONAL LUNCHEON DISCUSSION

ENJOY THE CONGRESS NETWORKING LUNCHEON OR ATTEND THIS OPTIONAL SMALL AND MID-SIZED LIFE SCIENCE COMPANIES LUNCHEON

12:00 pm – 1:00 pm Building Compliance from the Ground Up: A Roadmap for Small & Emerging Life Sciences Companies

Grab your box lunch and join a luncheon discussion designed for emerging and smaller life sciences companies that have limited to no existing compliance program elements. The focus is on helping compliance leaders determine where to begin and how to build a program in a practical, risk-based way.

The discussion will address questions such as:

- Which risks should be prioritized first?
- When should key compliance program elements and controls be implemented?
- How do you build a roadmap that aligns with the company's stage of growth?
- How do you maximize limited resources while establishing an effective compliance program

1:00 pm – 5:30 pm PHARMA/DEVICE CONGRESS OPENING PLENARY SESSION

1:00 pm Welcome and Introduction: PCF Board

1:15 pm C-Suite Congress Video Welcome

1:25 pm Keynote Annual OIG Update

2:15 pm Keynote US DOJ Criminal Division Update Fireside Chat

2:45 pm Tech & Human-in-the-Loop Compliance

(Why Human Judgment Matters More Than Ever)

3:15 pm Networking Break in Exhibit Hall

3:45 pm The Next Generation of Compliance: Leveraging Data to Stay Ahead of Risk

4:15 pm Integrated Risk Transformation in Pharma/Medical Device: From Compliance Burden to Strategic Advantage

4:45 pm Annual Chief Compliance Officers Fireside Chat

5:30 pm OPENING PLENARY SESSION ADJOURNMENT AND NETWORKING RECEPTION

AGENDA AT A GLANCE

DAY 3: THURSDAY, OCTOBER 15, 2026

7:00 am Registration Opens & Networking Breakfast in Exhibit Hall

PCF CHIEF COMPLIANCE OFFICER ROUNDTABLE (PCF-Sponsored, Exclusive Invitation-Only, Closed-Door Session)

7:00 am	Breakfast Buffet	10:00 am	Executive Breakout by Company Size — <i>Building AI Ready Teams</i>
8:00 am	CCO Roundtable Welcome and Introductions	10:40 am	Board Oversight of Compliance: What Audit Firms Observe and What Regulators Require
8:15 am	Future of the Compliance Profession in an AI Driven Environment	11:30 am	Open Forum: Opportunities for Benchmarking and Peer-driven Q&A. Bring your questions!
9:00 am	Executive Breakout by Company Size — <i>Leveraging AI to Support Compliance Programs</i>	11:55 am	Wrap-up
9:40 am	Networking Break	12:00 pm	Adjournment

8:00 am – 8:50 am

MORNING MINI SUMMITS: GROUP 5

MS24: Identifying and
Managing Risk Associated
with AI

MS25: Transparency
Reporting; Update on the
Centers for Medicare and
Medicaid Services Open
Payments Program

MS26: From Speak-Up to
Proof: Turning DOJ and OIG
Expectations into Defensible,
AI-Enabled Compliance
Operations

MS27: Manufacturer–
Specialty Pharmacy
Relationships: Managing
Compliance Risk in Specialty
and Rare-Disease Commercial
Models

MS28: The Future of
Compliance Monitoring:
AI Agents, Risk Intelligence
and Practical Adoption

9:00 am – 9:50 am

MORNING MINI SUMMITS: GROUP 6

MS29: Building the
Compliance Operating
Model for What's Next

MS30: Leveraging AI
for More Efficient and
Effective Investigations

MS31: Compliance
Considerations,
Enforcements and
Guidelines on Social
Media Activities

MS32: Building a
Compliance Roadmap:
Practical Strategies
for Scaling Compliance
Programs

MS33: Fair Market
Value in Flux:
Navigating Complex Fee
Arrangements, HCP &
Patient Engagement,
and Influencer
Compensation Risks

MS34: Future Proofing
the Compliance
Function: Operating
Models for an
AI-Enabled World

9:50 am – 10:10 am

NETWORKING BREAK IN EXHIBIT HALL

10:10 am – 11:00 am

MORNING MINI SUMMITS GROUP 7

MS35: Unstructured
Data and Advanced
Monitoring Strategies

MS36: Leading
Practices for Managing
Investigations Panel

MS37: From Makary to
Overton: Reflections
and Predictions on the
FDA's Priorities

MS38: Compliance
Considerations for Rare
Disease Products

MS39: From Oversight
to Partnership:
Strengthening
Collaboration Between
Compliance and the
Business

MS40: Digital
Ecosystem
Considerations for
Pharmaceutical
Companies

11:10 am – 12:00 pm

MORNING MINI SUMMITS GROUP 8

MS41: Holistic, Ongoing
Monitoring Case
Studies in Compliance

MS42: Emerging
Commercial & Market
Access Risk in Life
Sciences: Navigating
Innovation, Compliance,
and Evolving Access
Models

MS43: Effectively
Leveraging Post-
Investigation Mitigation
to Create a Narrative
of Continuous
Improvement

MS44: Data Analytics &
Compliance Monitoring
in an AI-Powered World

MS45: Can Learning
Data Reduce Risk?
Using Measurement
to Drive Defensible,
Risk-Based Compliance
Training

MS46: AI in Clinical
Practice: Compliance,
Governance & FDA
Oversight

12:00 PM – 1:10 PM

NETWORKING LUNCHEON WITH DESSERT AND COFFEE IN EXHIBIT HALL

12:10 pm – 1:00 pm

LUNCHEON MINI SUMMITS GROUP 9

MS47: Direct-to-
Consumer (DTC) Models
in the Pharmaceutical
Space

MS48: ROI of AI:
Separating Value from
Hype

MS49: Lean, Credible,
Defensible: Compliance
Programs That Work
Without Big Budgets

MS50: A Look Under the
Hood: Exploring PBM
and Payer Arrangement
Risks and Emerging
Reporting Requirements

MS51: Collaborating
to Create Lasting
Solutions During and
After Monitoring or
Investigations

MS52: Annual FDA
Office of Prescription
Drug Promotion Update

1:10 pm – 5:15 pm

CLOSING PLENARY SESSION

1:10 pm	Welcome and Introduction: PCF Board	3:15 pm	Networking Break in Exhibit Hall
1:15 pm	Keynote Annual DOJ Civil Division Update Fireside Chat	3:45 pm	Burgeoning Compliance Risks
1:45 pm	Investigations, Enforcement and Prosecutions Roundtable	4:15 pm	AI and the Evolving Compliance Function
2:15 pm	Updates from AdvaMed, BIO and PhRMA	4:45 pm	Managing Risk in Unsettled Times
2:45 pm	Market Access in 2026 and Beyond: A Shifting Compliance Landscape		

5:15 pm

CLOSING PLENARY SESSION ADJOURNMENT

AGENDA AT A GLANCE

DAY 4: FRIDAY, OCTOBER 16, 2026

7:00 am Breakfast Buffet

8:00 am – 12:00 pm **PCF INDUSTRY-ONLY COMPLIANCE BEST PRACTICES THINK TANK**
(Hosted by PCF: Industry-only Session for Pharmaceutical and Medical Device Company Ethics and Compliance Professionals and In-house Counsel only)

7:00 am	Breakfast Buffet	10:00 am	Networking Break
8:00 am	Welcome and Introductions	10:20 am	Customer-Centric Complexity: Meeting Customer Needs While Balancing Field Pressures
8:10 am	Inside the New DOJ Initiative: The Rising Importance of Data Miners	11:00 am	Breakouts by Company Size
8:45 am	Wins & Losses in the Early Days of AI – Audience Discussion Session	11:30 am	Last Minute Questions – Wrap Up
9:15 am	Benchmarking and Q&A Forum	12:00 pm	Congress Adjournment

12:00 pm CONGRESS ADJOURNMENT

DETAILED AGENDA

TUESDAY, OCTOBER 13, 2026

PHARMACEUTICAL AND MEDICAL DEVICE ETHICS AND COMPLIANCE CONGRESS DAY 1 (Included in standard Congress registration.)

11:00 am Registration Opens /Lunch on Your Own

FEATURING FIVE CONCURRENT SPECIAL FOCUSED SESSIONS

Focused Session 1: Whistleblower Complaints: From Hotline to Resolution: Managing Internal Investigations, Whistleblower Risk & Escalation Decisions

1:00 pm



Chair's Welcome and Introductions & DOJ/FCA Enforcement Trends: Lessons from Whistleblower Cases

John E. Kelly, JD, Partner and Chair, Healthcare Industry Practice, Barnes & Thornburg; Former Assistant Chief for Health Care Fraud, Criminal Division, Fraud Section, US Department of Justice; Washington, DC (Chair)

1:15 pm

A Fireside Chat with Nicholas C. Perros, JD, Senior Trial Counsel, Civil Division, Fraud Section, US DOJ

Nicholas C. Perros, JD, Senior Trial Counsel, Civil Division, Fraud Section, US Department of Justice; Washington, DC

Interviewed by:

John E. Kelly, JD, Partner and Chair, Healthcare Industry Practice, Barnes & Thornburg; Former Assistant Chief for Health Care Fraud, Criminal Division, Fraud Section, US Department of Justice; Washington, DC (Chair)

1:45 pm

Qui Tam Counsel Roundtable

Mary A. Inman, JD, Partner, Whistleblower Partners; Founding Member & Board Chair, Psst.org; Member of Advisory Board, Whistleblowing Canada Research Society; San Francisco, CA

Linda Severin, JD, Managing Member, Whistleblower Law Collaborative; Former Assistant US Attorney, Southern District of New York, US Department of Justice; Boston, MA

Gregg Shapiro, JD, Founder, Gregg Shapiro Law; Former Assistant US Attorney and Chief, Affirmative Civil Enforcement Unit, US Attorney's Office, District of Massachusetts, US Department of Justice; Boston, MA

Sarah M. Hall, JD, Partner, Member of the Firm, Epstein Becker Green; Former Trial Attorney, Fraud Section, Criminal Division, US Department of Justice; Washington, DC (Moderator)

2:30 pm

With Data and AI, Whistleblowers Set Off an FCA Tidal Wave

Avia M. Dunn, JD, MBA, Partner, Life Sciences, Skadden; Washington, DC

Stewart Kameen, JD, Partner, Davis Wright Tremaine; Former Senior Counsel, Industry Guidance Branch, Office of Counsel to the Inspector General, US Department of Health and Human Services, Washington, DC

3:15 pm

Networking Break

3:45 pm

Hotline Isn't Enough: Building a Smart Investigations Ecosystem

Michael Clarke, JD, CCEP, NACD.DC®, Principal, Jaeger-Plymouth Advisors; Retired Vice President, Deputy General Counsel & Global Chief Compliance Officer, ConvaTec; Former Vice President, Corporate Compliance, Indivior; Bridgewater, NJ (Former Pharma Congress Medical Device Executive Committee)

Saraswatha Lalitha Putcha, MA, Chief Operations Officer, Cresen Solutions; Philadelphia, PA (Moderator)

4:30 pm

Anatomy of an Internal Investigation

David J. Derusha, JD, Assistant General Counsel, Vertex Pharmaceuticals; Former Assistant US Attorney, US Attorney's Offices, District of Massachusetts, US Department of Justice; Boston, MA

Naveen Ganesh, MA, JD, Vice President, Global Head of Investigations, Ethics & Compliance, Takeda; Former Head of Investigations & Monitoring, North America & Global Specialty Care, Sanofi; Former Compliance Assurance & Investigations, Lead, Verily; Boston, MA

Sarah L. Whipple, JD, Principal, WhipEdge Solutions, Member, Rare Disease Compliance Consortium (RDCC); Former Vice President, Global Chief Compliance Officer, Apellis; Former Vice President, Legal & Chief Compliance Officer, Akebia; Needham, MA

Amanda P. Masselam Strachan, JD, Partner, WilmerHale; Former Chief, Criminal Division, US Attorney's Office for the District of Massachusetts; Former Assistant US Attorney, US Attorneys' Offices, US Department of Justice; Boston, MA (Moderator)

5:15 pm

Managing Whistleblower Risk and Internal Escalation

Jennifer Beaudoin, CFE, CPA, Executive Director, Head of Global Compliance Program Strategy, Governance and Transformation, Vertex Pharmaceuticals; Boston, MA


Warren T. Allen II, MPP, JD, Principal, Miles & Stockbridge; Professorial Lecturer in Law (White Collar Crime), The George Washington University Law School; Washington, DC (Co-Moderator)

David Amendola, Director, Life Sciences, Resolution Economics; Former Global Compliance Risk, Evaluation & Management, ConvaTec; New York, NY (Co-Moderator)

Adjournment

Focused Session 2: Pharmaceutical and Medical Device Advanced Privacy and Security/ Cybersecurity Updates

1:00 pm Chair's Welcome, Overview and Introductions



Mary Devlin Capizzi, JD, MBA, Partner, Faegre Drinker; General Counsel, International Pharmaceutical and Medical Device Privacy Consortium; Washington, DC (Chair)

1:15 pm The Basics of Healthcare Privacy for Compliance Professionals and an Overview of Privacy Issues Unique to Pharmaceutical and Medical Device Enterprises

Adam Greene, JD, MPH, Partner and Co-chair, Health Information & HIPAA Practice, Davis Wright Tremaine; Former Senior Health Information Technology and Privacy Specialist, Office for Civil Rights, US Department of Health & Human Services, Washington, DC

1:45 pm IAPP Presents: Privacy, AI Compliance, and Beyond for the Future of Pharma and Medical Devices

Melissa Bianchi, JD, Partner and Leader, Firm's Digital Health Initiative, Hogan Lovells Cadwalader; Washington, DC

Patrice Ettinger, JD, CIPP/US, Vice President, Chief Privacy Officer, Regeneron; Former Chief Privacy Officer, Pfizer; Former Chief Privacy Officer, Avon; Past Chair, International Association of Privacy Professionals; New York, NY

Gabe Maldoff, JD, Partner, Data, Privacy, and Cybersecurity practice, Goodwin Procter; Adjunct Professor, Maine Law School, Washington, DC

Cobun Zweifel-Keegan, JD, CIPP/US, CIPM, Managing Director, IAPP; Former Deputy Director, Privacy Initiatives, Better Business Bureau; Washington DC (Moderator)

2:30 pm

The International Pharmaceutical and Medical Device Privacy Consortium Presents Advanced Strategies for Addressing Privacy and Cybersecurity Issues for Life Sciences Companies

Kimberly J. Gold, JD, Chief Privacy Officer, Senior Associate General Counsel and Executive Director, Privacy Law, Genentech; Former Privacy Seconded, Pfizer; San Francisco, CA

Tahvia Jenkins, JD, CIPP/US, US Privacy Officer & Counsel, Sanofi; Former Assistant Counsel, Health Affairs, Privacy, and Data Protection, University of California, Cambridge, MA

Danielle Manner, JD, Chief Privacy Officer and Senior Associate General Counsel, Gilead; Former Senior Privacy Counsel, Pfizer; Chicago, IL

Mary Devlin Capizzi, JD, MBA, Partner, Faegre Drinker; General Counsel, International Pharmaceutical and Medical Device Privacy Consortium; Washington, DC (Moderator)

3:15 pm

Companies from the Cybersecurity Working Group, Health Sector Coordinating Council

Gregory T. Garcia, Executive Director, Cybersecurity Working Group, Health Sector Coordinating Council; Former Assistant Secretary for Cybersecurity, US Department of Homeland Security; Washington, DC

3:45 pm

Networking Break

4:15 pm

Cybersecurity Best Practices for Pharma and Medical Device

David J. Scott, MS, Managing Director, Forensic & Integrity Services, EY; Former Assistant Director, Counterterrorism, and Head, Operations Branch, Cyber Division, Director, National Cyber Investigative Joint Task Force, Federal Bureau of Investigation; Leesburg, VA

5:00 pm

Session Faculty Q&A


Jamie E. Darch, JD, Partner, HIPAA and State Data Privacy & Cybersecurity Law, Ropes & Gray; Chicago, IL (Moderator)

5:45 pm

Adjournment

Focused Session 3: Managing Medical-Commercial Interactions: Strategic Collaboration, Evolving Roles & Risk-Based Governance

1:00 pm Co-Chair's Introductions & Session Overview



Peter Agnoletto, CPA, Compliance Officer, General Medicines and Consumer Health Care, Sanofi; Former Senior Director, Chief Compliance Officer & Chief Audit Executive & ERM Leader, Par Pharmaceutical Companies; Bridgewater, NJ (Co-Chair)



Jillian A. Gillespie, MBA, Senior Director, Compliance, Medical & Medical Affairs, Pfizer; Former Director, Compliance Business Partner, R&D, Medical Affairs, HEOR; Chicago, IL (Co-Chair)

1:15 pm Strategic Planning Together, Tactical Execution Separately: Practical Case Studies in Medical-Commercial Collaboration

Jillian A. Gillespie, MBA, Senior Director, Compliance, Medical & Medical Affairs, Pfizer; Former Director, Compliance Business Partner, R&D, Medical Affairs, HEOR; Chicago, IL

2:00 pm

Samantha Brabant Philis, MS, Director, E&C Policy, Training, and Business Operations, Jazz Pharmaceuticals; Former North America Compliance Manager, Cushman & Wakefield; Chicago, IL

Samantha Sutherland, Director, Life Sciences Consulting Practice, Baker Tilly; Jersey City, NJ (Moderator)

Beyond Sales Representatives and MSLs: Understanding Emerging Field-Based Roles and Governance Challenges

Sri Burra, MBA, Director, US Ethics and Compliance, Organon; Former Ethics & Compliance Lead, North America, Haleon; Former Transformation Lead, Ethics & Compliance Workstream GSK; Malvern, PA

Amy Wilson, MSJ, Vice President, Chief Compliance Officer, Esperion; Former Head of U.S. Compliance, MorphoSys; Former Director, Enterprise Compliance, Alexion Pharmaceuticals; Boston, MA

Matt Chandler, JD, Director, Epsilon Life Sciences; Richmond, VA (Moderator)

Session continued next page

Focused Session 3 *continued***2:45 pm** **Networking Break****3:15 pm** **Protecting Medical Independence While Enabling Strategic Cross-Functional Collaboration**

Peter Lee, JD, LLM, Chief Compliance Officer, Kura Oncology; Former Chief Compliance Officer, Mirati Therapeutics; Former Chief Compliance Officer, Heron Therapeutics; San Diego, CA

Stefanie A. Doebler, JD, Partner and Co-Chair, Health Care Practice Group, Covington & Burling; Washington, DC (Co-Moderator)

Sarah A. Franklin, JD, Partner and Vice-Chair, Life Sciences Investigations Practice, Covington & Burling; Former Attorney, US Federal Trade Commission; Washington, DC (Co-Moderator)

4:00 pm **Medical–Commercial Boundaries: Congresses, Sponsorships & Promotional Risk**

Akosua Tuffuor, JD, Corporate Counsel, US General Medicines, Sanofi; Morristown, NJ/Washington, DC

Maureen Cawley, JD, Senior Director, Corporate Counsel, Incyte; Former Global Agreements Attorney, Merck; Philadelphia, PA

4:45 pm

Achsah Warren, MSJ, Vice President, Head of Compliance, Sumitomo Pharma America; Former Vice President Compliance, Urovant Sciences; Former Senior Compliance Manager, Allergan, Irvine, CA

Mahnu V. Davar, MA, JD, Partner and Co-chair, Life Sciences & Healthcare Regulatory, Arnold & Porter; Washington, DC (Moderator)

Have We Become Too Restrictive? Rethinking Medical–Commercial Governance for the Next Era

Giulia Del Cane, MBA, Ethics & Business Integrity Strategic Advisor, Global and US Specialty Care, Sanofi; Boston, MA

Peter Agnoletto, CPA, Compliance Officer, General Medicines and Consumer Health Care, Sanofi; Former Senior Director, Chief Compliance Officer & Chief Audit Executive & ERM Leader, Par Pharmaceutical Companies, Bridgewater, NJ (Co-Chair)

Jillian A. Gillespie, MBA, Senior Director, Compliance, Medical & Medical Affairs, Pfizer; Former Director, Compliance Business Partner, R&D, Medical Affairs, HEOR; Chicago, IL (Co-Chair)

5:30 pm**Adjournment****Focused Session 4: AI in Action: Real-World Compliance Case Studies from the Front Lines of AI Use in Life Science Compliance Departments****1:00 pm**

Chair's Welcome and Introductions and AI Basics, Life Science Industry Ethics and Compliance Applications

John Poulin, Chief Technology Officer and Partner, HELIO; Boston, MA (Chair)

1:30 pm

A Brief Overview of the Epsilon & qordata AI Use Compliance Survey

Casey J. Horton, CFE, Managing Director, Epsilon Life Sciences; Former Director, Compliance Operations, AbbVie; Chicago, IL

Mohammad Ovais, Founder & Board Member, qordata; Chief Executive Officer, Managing Director, Veraqor; Princeton, NJ

2:00 pm

Facilitated Case Study Discussion: From Transcript to Insights: How Compliance Teams Are Using AI to Transform Investigations

Briana Cabrera, MS, CFE, Senior Director, Global Privacy & Compliance, Investigations, Medtronic, Miami, FL

Alexis Shaw, Vice President, Head of Healthcare Compliance, Paratek Pharmaceuticals; Former Compliance Officer, Endo Pharmaceuticals; Former Global Compliance Investigations Manager, Boston Scientific; King of Prussia, PA

Minna Bak, MBA, Managing Director, HELIO; Boston, MA (Moderator)

2:30 pm

Facilitated Case Study Discussion: AI Governing AI: Leveraging Artificial Intelligence to Develop Effective Governance Policies

Marla Izbicky, JD, Senior Director, Senior Corporate Counsel, Harmony Biosciences; Chicago, IL

Neeraj Gupta, MBA, President, Chief Technology Officer, Cresen Solutions; Chester Springs, PA (Moderator)

3:00 pm**Networking Break****3:15 pm**

Facilitated Case Study Discussion: AI-Assisted Monitoring and Detection of Potential Policy Violations

Ron Strauss, Vice President Compliance, MiMedx; Former Sales Leader, Osteo Specialty, Eli Lilly and Company; Marietta, GA

John Poulin, Chief Technology Officer and Partner, HELIO; Boston, MA (Moderator)

3:45 pm

Facilitated Case Study Discussion: Agentic AI Use for Continuous Risk Assessment (vs Annual)

Matthew Stasiunas, PMP, CCEP, LPEC, RAMP & Project Management Lead, Indivior; Former Senior Specialist, Integrity and Compliance, Kaléo; Richmond, VA

Michael L. Shaw, JD, Global Head of Compliance, Privacy and Risk, ZS; Former Vice President and Compliance Officer, GSK; Former Senior Counsel, Office of Inspector General, US Department of Health and Human Services; Princeton, NJ (Moderator)

4:15 pm

The Unspoken Risk of AI: Moral Outsourcing — and Why “Add Human Judgment” Isn’t Enough

Benjamin Correa, JD, Partner, Food, Drug & Medical Device, Sidley Austin; Washington, DC

Stacy E. Yeung, JD, Vice President, General Counsel and Corporate Secretary, SELLAS Life Sciences Group; Former Assistant General Counsel, Arena Pharmaceuticals; Former Deputy General Counsel, DBV Technologies; New York, NY

L. Stephan Vincze, JD, LLM, MBA, President and Chief Executive Officer, TRESTLE Compliance; Former Senior Vice President and Chief Compliance Officer, Warner Chilcot; Former Vice President, Ethics and Compliance Officer, TAP Pharmaceutical; Boston, MA (Moderator)

Session continued next page

Focused Session 4 *continued***5:00 pm****The Health Care Compliance Association Presents: Advanced Strategies in Using AI to Monitor and Improve Compliance: Lessons from Other Healthcare Sectors**

Joan Podleski, CCEP, CHPC, CHRC, CHC, Vice President & Chief Privacy Officer, Children's Health System of Texas; Former Director, Institutional Ethics & Compliance Program, Duke University; Dallas, TX

5:45 pm

R. Brett Short, CHC, CHPC, CHRC, Chief Compliance Officer and Chief Privacy Officer, University of Kentucky; Board & Immediate Past Chair, Health Care Compliance Association; Lexington, KY

Betsy Wade, MPH, CHC, CHPC, CAN, Chief Compliance & Ethics Officer, Signature Healthcare; Board & Treasurer, Health Care Compliance Association; Louisville, KY

Adjournment**Focused Session 5: GP 101: A Primer on the Fundamentals of Government Pricing for Compliance Officers & The Evolving Pricing and Contracting Landscape: What Compliance Officers Need to Know****1:00 pm****Chair's Introductions & Session Overview**

Chris Cobourn, MS, Managing Director Government Programs Practice Lead, HELIO; Placida, FL (Chair)

1:15 pm**GP 101: A Primer on the Fundamentals of Government Pricing for Compliance Officers**

Tracy Mumpower, Director Managed Services, Life Science Revenue Management, Government Pricing & Commercial Contracting, HELIO; Former Manager, Commercial Contract Administration, King Pharmaceuticals; Bristol, VA

John Shakow, JD, Pharmaceutical Government Price Reporting Expert; Partner, FDA & Life Sciences Practice, King & Spalding; Washington, DC

Chris Cobourn, MS, Managing Director Government Programs Practice Lead, HELIO; Placida, FL (Moderator)

3:30 pm**Networking Break****4:00 pm****The Evolving Pricing and Contracting Landscape: What Compliance Officers Need to Know**

Kristie Champlin Gurley, JD, Partner, Covington & Burling; Former Counsel, Office of the General Counsel, CMS Division, US Department of Health and Human Services; Washington, DC

Kristin M. Hicks, JD, Partner, Life Sciences & Healthcare Regulatory, Arnold & Porter; Washington, DC

Tracy Mumpower, Director Managed Services, Life Science Revenue Management, Government Pricing & Commercial Contracting, HELIO; Former Manager, Commercial Contract Administration, King Pharmaceuticals; Bristol, VA

Stephanie Trunk, JD, Partner, Life Science Practice Group, Arent Fox; Former Legal Counsel, Catalyst Health Solutions; Washington, DC

Chris Cobourn, MS, Managing Director Government Programs Practice Lead, HELIO; Placida, FL (Moderator)

5:30 pm**Adjournment**

WEDNESDAY, OCTOBER 14, 2026**PHARMACEUTICAL AND MEDICAL DEVICE ETHICS AND COMPLIANCE CONGRESS DAY 2**

7:00 am **Registration Opens & Networking Breakfast in Exhibit Hall**

MORNING MINI SUMMITS: GROUP 1 (8:00 am - 8:50 am)**Mini Summit 1: Compliance Independence in The Real World: Governance Models That Work**

8:00 am **Introductions, Discussions and Q&A**

Kathy Johnson, JD, *Vice President, Commercial and Development Legal, Vertex Pharmaceuticals; Former US Legal Counsel Consultant, Takeda; Former Senior Director, Legal Counsel, Shire; Boston, MA*

Stefanie A. Doebler, JD, *Partner and Co-Chair, Health Care Practice Group, Covington & Burling; Washington, DC (Co-Moderator)*

Sarah A. Franklin, JD, *Partner and Vice-Chair, Life Sciences Investigations Practice, Covington & Burling; Former Attorney, US Federal Trade Commission; Washington, DC (Co-Moderator)*

Mini Summit 2: The Agentic Compliance Function of the Future

As pharmaceutical organizations accelerate adoption of AI, automation, and agentic technologies across R&D, manufacturing, commercial operations, and corporate functions, the compliance function must evolve beyond traditional oversight models. Increasing regulatory complexity, expanding digital ecosystems, heightened expectations for transparency, and the emergence of autonomous decision-making systems are reshaping how organizations govern risk, ethics, and accountability at enterprise scale. This presentation explores how leading organizations are reimagining the compliance function through an agentic, AI-enabled operating model that transforms compliance from a reactive control function into a strategic trust and transformation capability.

Attendees will gain insights into:

- Embedding “Trust by Design” principles into AI-enabled business processes, digital transformation initiatives, and operational workflows
- Translating policy and regulatory expectations into operational guardrails, oversight thresholds, and accountable governance structures
- Leveraging agentic monitoring, automation, and AI-native surveillance capabilities for continuous compliance oversight and anomaly detection
- Designing scalable human-in-the-loop oversight models for AI-assisted and autonomous business activities
- Creating integrated risk intelligence capabilities that provide real-time visibility across compliance, operational, cyber, privacy, and strategic risk domains

The session will also highlight practical implementation considerations, organizational design implications, governance challenges, and emerging leading practices shaping the future of compliance in the pharmaceutical industry. Participants will leave with actionable perspectives on how agentic technologies, integrated governance, and AI-enabled oversight can redefine the compliance function into a proactive, scalable, and strategic enabler of innovation, trust, and enterprise performance.

8:00 am

Introductions, Discussions and Q&A

Jennifer Beaudoin, CFE, CPA, *Executive Director, Head of Global Compliance Program Strategy, Governance and Transformation, Vertex Pharmaceuticals; Boston, MA*

Emily Cunningham, *Associate Director, Compliance, Ultragenyx; New York, NY*

Lauren H. Thal, *Vice President, Compliance, Tolmar; Former Compliance Officer, Cerapedics; Former Senior Director of Compliance, Beta Bionics; Chicago, IL*

Emily (Jaffe) Singh, *Partner, Global Spend Transparency Practice Leader, PwC; Chicago, IL (Moderator)*

Mini Summit 3: Evolution of Patient Finding Activities

As therapies become more targeted and bespoke, particularly in the treatment of rare diseases, the accurate identification of appropriate patients has become a growing priority for manufacturers. Sponsored genetic testing programs are among the more widely adopted approaches to support diagnosis and patient identification, but additional patient finding strategies are emerging rapidly. This panel will explore new and evolving patient identification activities and examine the legal, compliance, and privacy considerations they may raise.

8:00 am

Introductions, Discussions and Q&A

Betania Glorio, *Senior Vice President, Chief Compliance Officer, Avidity Biosciences; Former Chief Compliance Officer and Head of Group Compliance and Data Privacy, EMD Serono; Former Global Head of Compliance, Healthcare, Merck KGaA Boston, MA*

Jesse Siegel, JD, *Head of Business Ethics, Americas, Ipsen; Former Senior Counsel, Neurology & Immunology, EMD Serono; Cambridge, MA*

Sara K. Frank, JD, *Principal, Choate Hall & Stewart; Boston, MA (Moderator)*

Mini Summit 4: First Product Launch: Policy Development Strategies and Techniques

A forward-looking discussion on how geopolitical developments are influencing enforcement priorities and how compliance programs should be structured today to withstand future DOJ scrutiny (e.g., 2028–2032 outlook). The session would also explore the balance between conduct and cooperation, and the importance of documentation and strategic planning.

8:00 am

Introductions, Discussions and Q&A

Michael Morgan, MBA, CCEP, *Global Compliance Officer, Telix Pharmaceuticals (US); Member, Business Ethics Indiana; Former Ethics and Compliance Officer-North America, Corteva; Indianapolis, IN*

Sandra Park, JD, *Senior Vice President, Legal & Chief Compliance Officer, Vera Therapeutics; Former General Counsel & Chief Compliance Officer, IDEology Health; Former Vice President, Commercial Legal, Kite, a Gilead Company; Brisbane, CA*

Hannah Putnam, MHA, CHC, CHRC, *Head of Ethics & Compliance Operations, Oncology, Takeda; Former Senior Director, Ethics & Compliance, Veloxis; Former Senior Corporate Ethics & Compliance Officer, Fresenius; Cambridge, MA*

Yogesh Bahl, MBA, *Partner and Practice Leader, Resolution Life Sciences and Healthcare; Chief Financial Officer and Head of Investor Relations, IACTA Pharmaceuticals; New York, NY (Moderator)*

Mini Summit 5: Speaker Programs in 2026: Practical Legal and Compliance Considerations for Executing from Beginning to End Amid Ongoing Scrutiny

1. What patterns can be observed and lessons learned from continued government scrutiny, enforcement activity, and evolving expectations? What are some key legal and compliance themes?
2. How can compliance, legal, and regulatory teams work with their colleagues to implement compliance standards and strategies?
3. What types of challenges can arise and how can they be addressed?

8:00 am Introductions, Discussions and Q&A

Sharon R. Delshad, JD, Senior Director, Legal-Compliance Counsel, Travele Therapeutics; San Diego, CA

Tracey Hannon, JD, Director, Compliance Business Partner, Alexion Pharmaceuticals; Former Compliance Counsel, Ionis Pharmaceuticals; Boston, MA

Lauren Ann Pond, JD, Assistant General Counsel, BridgeBio; Former Commercial Counsel, Biogen; Former Counsel, Takeda; Palo Alto, CA

Noah C. Goldstein, JD, Counsel, Pharma, Biotech & Medical Device Legal, Regulatory, & Compliance, Porzio Bromberg & Newman; Westborough, MA (Moderator)

8:50 am Transition Break

MORNING MINI SUMMITS: GROUP 2 (9:00 am - 9:50 am)

Mini Summit 6: From Pronouncements to Practice: Understanding DOJ Enforcement Priorities

Join this session for a critical discussion of how DOJ's enforcement priorities are taking shape in practice. We'll share insights on enforcement trends and draw from recent matters (from the sources of these cases to the activities that were scrutinized and how the results aligned with DOJ policy) for an engaging discussion for in-house compliance and legal professionals around the practical considerations and implications of these latest developments for compliance programs.

9:00 am Introductions, Discussions and Q&A

Christina O. Hud, JD, Senior Counsel, Global Investigations, Pfizer; Former Health Care Fraud Acting Unit Chief and Senior Trial Counsel at US Department of Justice, US Attorney's Office for the District of New Jersey; New York, NY

Michelle Dineen Jerrett, JD, Regional Head of Investigations & Monitoring, North America, Sanofi; Former Legal Director, Endoscopy, Boston Scientific; Former Assistant United States Attorney, US Attorney's Office, District of Massachusetts; Cambridge, MA

Emily Treanor, JD, Head of Global Investigations & Enterprise Risk Management, Alnylam Pharmaceuticals; Washington, DC

Jane H. Yoon, JD, Partner, Litigation Department, Paul Hastings; Former Assistant United States Attorney, Health Care and Government Fraud Unit, US Attorney's Office for the District of New Jersey; New York, NY (Moderator)

Mini Summit 7: Boring is Risky! Want Stronger Ethics and Compliance Engagement? Train & Communicate Colorfully

Boring is your program's worst enemy. You have so many important things to share, but it all falls apart if employees are tuning you out. People do not speak up to ask questions or report concerns when they're bored, annoyed or afraid.

In this session we'll share creative, practical strategies and success stories and we'll show you real examples inspired by great TV that employees want to binge like Netflix. Tune in to learn how to:

- Change E&C's vibe to create a positive identity and brand
- Get attention and increase E&C awareness all year
- Improve learning engagement while taking up less time
- Generate influence & create E&C influencers

9:00 am Introductions, Discussions and Q&A

Regina Gore Cavaliere, JD, Chief Ethics and Compliance Officer, Vice President Regulatory and Compliance, Henry Schein; Melville, NY

Ronnie H. Feldman, Founder, Chief Executive Officer and Creative Director, Learnings & Entertainment: Comedians Who Improve Compliance; Chicago, IL

Mini Summit 8: Best Practices for Data Analytics

Recent enforcement actions have turned manufacturers' own speaker logs, meal records, call notes, and prescribing trends into evidence, putting a pointed question to compliance teams: can they get to the same data, and act on what it shows in time to matter? This panel moves beyond the dashboard. We'll examine how teams set analytics strategy, close the loop from signal to remediation, and govern the use of AI in monitoring and review, including where detection creates its own obligation to act. Panelists will speak to building a credible analytics function at any scale, from a one-person program to a global monitoring team.

9:00 am Introductions, Discussions and Q&A

Bobby Carnathan, Senior Manager, Ethics and Compliance Business Partner, Novo Nordisk; Plainsboro, NJ

Christian Malias, MBA, Associate Director, Compliance Program Development, Insmmed; Former Associate Director Compliance Business Partner, Sage Therapeutics; Former Global Corporate Compliance Manager, Adaptimmune; Pittsburgh, PA

Erica Powers, CHC, Founder & Chief Executive Officer, Ethical Paths; Former Vice President, Chief Compliance Officer, Sage Therapeutics; Former Director Corporate Compliance, Vertex Pharmaceuticals; Boston, MA (Moderator)

Mini Summit 9: On the Front Lines: Navigating Field Force and Sales Compliance Risk

- Compliance risks associated with speaker programs, meals, and HCP interactions
- Sampling controls, documentation risks, and recent enforcement focus areas
- State law developments impacting field activities like disclosures and licensing
- Sales incentive compensation and unintended behavioral risk

9:00 am Introductions, Discussions and Q&A

Ron Strauss, Vice President Compliance, MiMedx; Former Sales Leader, Osteo Specialty, Eli Lilly and Company; Marietta, GA

Sarah L. Whipple, JD, Principal, WhipEdge Solutions; Member, Rare Disease Compliance Consortium (RDCC); Former Vice President, Global Chief Compliance Officer, Apellis; Former Vice President, Legal & Chief Compliance Officer, Akebia; Needham, MA

Brian Van Hoy, RPh, Vice President of Compliance, G&M Health; Former Director, Compliance & Ethics, Eli Lilly and Company; Somerset, NJ (Moderator)

Mini Summit 10: Communicating the Story on Integrity: What Compliance Leaders Can Learn from Health Stakeholders

Compliance leaders are asked not only to build and sustain effective integrity programs with employees, but to inform business decisions that impact external stakeholder trust. They are also increasingly asked to engage directly with external stakeholders to share and improve their company's practices, from trade associations to collective action initiatives. This session will provide practical insights to help you and your team better communicate the story of integrity when it impacts an external audience, drawing on diverse stakeholder perspectives and experiences from partnerships such as the U.S. Consensus Framework for Ethical Collaboration.

9:00 am Introductions, Discussions and Q&A

Paul M. Johnson, JD, Associate Vice President, Deputy Chief Compliance Officer, Global Compliance, Amgen; Former Senior Counsel, Office of Counsel to the Inspector General, US Department of Health and Human Services; Thousand Oaks, CA

Karen Mancera-Cuevas, DrPH, MS, MPH, Senior Director, Research Advancement & Equity, National Health Council; Former Deputy Director, Health Promotion, Illinois Department of Public Health, Washington, DC

Julie Ritchie Wagner, JD, Assistant General Counsel, PhRMA; Former Senior Counsel, Office of Counsel to the Inspector General, US Department of Health and Human Services; Washington, DC

Andrew Blasi, MBA, Founder & Chief Executive Officer, Ethicist International; Founding Member, Anti-Corruption Leaders Hub, OECD; Faculty, International Anti-Corruption Academy; Washington, DC (Moderator)

Mini Summit 11: Designing HCP Engagement with Transparency Built In

As regulatory scrutiny around HCP engagement increases, organizations must ensure transparency is embedded into their processes. This session explores how to design systems that capture required data and leverage AI.

9:00 am Introductions, Discussions and Q&A

Kaoutar Afif, Manager, Ethics & Compliance, Cardinal Health; Dublin, OH

Peggy Kruk, HMCC, Compliance Manager, MiMedX; Former Director, Compliance, Program Services, Vaniam Group; Dallas, GA

Jacob Wolf, MBA, Chief Commercial Officer, Cresen Solutions; Orlando, FL (Moderator)

9:50 am Networking Break in Exhibit Hall

MORNING MINI SUMMITS: GROUP 3 (10:10 am – 11:00 am)

Mini Summit 12: Compliance and M&A: Why Early Engagement Matters

Compliance issues can affect deal value, integration, and post-close risk—yet compliance is often brought in too late. This session explores how early engagement helps teams identify risks sooner, make better decisions, and avoid costly surprises throughout the deal lifecycle.

10:10 am Introductions, Discussions and Q&A

Eliza L. Andonova, JD, Partner, Global Regulatory, Hogan Lovells Cadwalader; Washington, DC

Eric Nichols, JD, Associate Vice President, Ethics & Compliance, R&D and Business Development, Eli Lilly and Company; Indianapolis, IN

Megan Roberts, CPA, MS, Head of Integrity & Compliance, Par Health; Former Senior Director, Integrity & Compliance; St. Louis, MO

Heather Young, JD, Senior Director, Compliance Officer, Global Business Partner, Olympus Corporation of the Americas; Former Assistant District Attorney, Philadelphia District Attorney's Office, Philadelphia, PA; Center Valley, PA

Russell Rose, JD, Managing Director, Deloitte Consulting; Dallas, TX (Moderator)

Mini Summit 13: The State of Medical Device Compliance: Annual Industry Roundtable

10:10 am Introductions, Discussions and Q&A

Kate Godfrey, JD, CCEP, Senior Vice President, Global Chief Compliance Officer, Chief Compliance Officer KSNA, Karl Storz North America; El Segundo, CA

JJ Kuhn, JD, Chief Ethics & Compliance Officer, Danaher; Former Senior Vice President and Chief Ethics & Compliance Officer, Solventum; Former Vice President Chief Counsel, Global Investigations, Medtronic; Minneapolis, MN (Pharma Congress Medical Device Executive Committee)

Diane Seol, JD, Of Counsel, Choate Hall & Stewart; Former Assistant United States Attorney, Affirmative Civil Enforcement Unit, US Attorney's Office, District of Massachusetts; Boston, MA

Casey J. Horton, CFE, Managing Director, Epsilon Life Sciences; Former Director, Compliance Operations, AbbVie; Chicago, IL (Moderator)

Mini Summit 14: The State We're In: Legal & Enforcement Trends Reshaping Pharmaceutical Compliance

- Recent and upcoming state law developments affecting pharmaceutical manufacturers
- Trends in proposed legislation, such as A.I., disclosures, advertising, and more
- Commonly overlooked requirements creating hidden compliance exposure
- Review of recent OIG enforcement actions and Advisory Opinions impacting life sciences organization
- Key themes and patterns emerging from enforcement activity across the industry

10:10 am Introductions, Discussions and Q&A

Stefanie L. Hill, JD, Senior Director, Global Ethics & Compliance, Emergent BioSolutions; Former Senior Compliance Counsel, Prolacta Bioscience; Former Director, Compliance Counsel, Otsuka Pharmaceutical Companies; Gaithersburg, MD

Danielle Santiago, JD, Director, Legal Affairs Specialist, Otsuka Pharmaceutical Companies, US; Corporate Secretary, Sozosei Foundation; President, HBA Miami Chapter, SE Region, Volunteer Board Member, Healthcare Businesswomen's Association; Assistant Corporate Secretary, Jnana Therapeutics; Miami, FL

Olivia Krzeminski, JD, Director of Compliance & Legal Research, G&M Health; Somerset, NJ (Moderator)

Mini Summit 15: External Funding Risks and Mitigation: Latest Trends in Exhibit & Display and Sponsorship Requests

10:10 am Introductions, Discussions and Q&A

Asha Green, JD, MPA, CCEP, CHC, Director, US Compliance, Ferring; Former Global Head, I&C Risk Assessment and Mitigation Planning and Senior Business Advisor, Indivior; Parsippany, NJ

Alison J. Page, JD, Assistant General Counsel, Oncology and US Market Access & Patient Services Compliance Lead, Pfizer; New York, NY

Samantha Barrett Badlam, JD, Partner, Litigation & Enforcement Group, Ropes & Gray; Washington, DC (Moderator)

Mini Summit 16: Beyond the Questionnaire: Building a Risk-Based Third-Party Management Program That Actually Works

Third party risk management too often calcifies into a check-the-box exercise with a questionnaire at onboarding, then silence until renewal. Meanwhile, real risk emerges dynamically: ownership changes, sanctions designations, sub-distributors operating three tiers beyond visibility. This panel examines how leading life science companies are rebuilding their third-party risk management around how risk actually behaves. Panelists will share practical approaches to meaningful risk-tiering, the shift from point-in-time diligence to continuous monitoring, and where AI-driven screening ends and human intelligence must begin.

10:10 am Introductions, Discussions and Q&A

Ariadna Quesada, MSJ, *Vice President of Compliance - Global Compliance & Privacy lead, Zoll Medical; Former Compliance Director Europe & MEATI, Hillrom; Former Ethics and Compliance Officer, The Netherlands, AbbVie; Madrid, Spain*

Suki Wiltman, *Vice President, Global Ethics & Compliance, Ipsen; Former Business Partner, Governance, Ethics & Compliance, GSK; Former Senior Corporate Compliance Manager, Allergan Canada; Toronto, Canada*

David Fisher, MS, *President, TDI Solutions; Former Vice President & General Manager, Cyber Innovations, Battelle; Washington, DC (Moderator)*

Mini Summit 17: Navigating Today's Enforcement Landscape with Culture, Data, and Ethics

Participants will explore:

- Are traditional assumptions about enforcement risk still valid?
- When does self-disclosure make strategic sense, and when might it not?
- How can organizations measure whether compliance programs are actually working?
- What data boards and executives are demanding to make better risk decisions?
- How can companies thrive in an environment where certainty is decreasing and scrutiny remains high?

10:10 am Introductions, Discussions and Q&A

Hui Chen, JD, *Co-Founder, Culture. Data. Ethics; Former Compliance Counsel Expert (Consultant), US Department of Justice; Former Assistant General Counsel, Pfizer; Honolulu, HI*

Zachary Coseglia, JD, *Co-Founder, Culture. Data. Ethics; Co-Founder & Former Managing Principal & Head of Innovation R&G Insights Lab, Ropes & Gray; Former Vice President & Assistant General Counsel, Global Compliance Monitoring, Analytics and Digital, Pfizer; Boston, MA*

11:00 am Transition Break

MORNING MINI SUMMITS: GROUP 4 (11:10 am – 12:00 pm)

Mini Summit 18: Risk Advantage: How Resilient Organizations are Capturing Opportunity through Uncertainty

Recent enforcement actions have turned manufacturers' own speaker logs, meal records, call notes, and prescribing trends into evidence, putting a pointed question to compliance teams: can they get to the same data, and act on what it shows in time to matter? This panel moves beyond the dashboard. We'll examine how teams set analytics strategy, close the

loop from signal to remediation, and govern the use of AI in monitoring and review, including where detection creates its own obligation to act. Panelists will speak to building a credible analytics function at any scale, from a one-person program to a global monitoring team.

11:10 am Introductions, Discussions and Q&A

Kate Godfrey, JD, CCEP, *Senior Vice President, Global Chief Compliance Officer, Chief Compliance Officer KSNA, Karl Storz North America; El Segundo, CA*

Anisa Dhalla, *Vice President, Chief Ethics and Compliance Officer; Global Head, Ethics and Compliance, UCB; Atlanta, GA (PCF Board Member)*

Russell Schaefer, MBA, *Managing Director, BCG; Washington, DC (Moderator)*

Mini Summit 19: View from the Top: Practical Advice for Accelerating Your Compliance Career

11:10 am Introductions, Discussions and Q&A

Terra Buckley, JD, *Chief Compliance & Ethics Officer, Bristol Myers Squibb; Former Chief Compliance Officer, LivaNova; Former Executive Director, Head, Business Advisory Center of Excellence, US Healthcare Compliance, Celgene; Summit, NJ*

Christie Camelio, *Senior Vice President and Chief Compliance Officer, Insmed; Former Vice President & Deputy Global CCO, Celgene; Florham Park, NJ (PCF Board)*

Daryl Kreml, JD, *Head, Ethics & Compliance, Global Oncology, Takeda; Former Senior Vice President, Chief Enterprise, Risk & Compliance Officer, Sage; Former US Compliance & Global Program Management, Biogen; Boston Scientific; Boston, MA (PCF Board Member)*

Daniel O'Connor, *Senior Vice President, NXLevel Compliance; Lambertville, NJ (Moderator)*

Mini Summit 20: Direct-to-Consumer (DTC) Models: Emerging Compliance Risks and Governance Considerations

As pharmaceutical and medical device companies continue to explore direct-to-consumer models, including telehealth partnerships, online prescribing platforms, patient support services, and direct distribution channels, compliance professionals are facing new and evolving risk areas. Potential discussion areas could include:

- Anti-Kickback Statute and False Claims Act considerations
- Relationships with telehealth providers and third-party vendors
- Patient inducement concerns
- Marketing and promotional oversight
- Data privacy and patient information considerations
- Governance and monitoring of DTC programs
- Lessons learned from recent enforcement actions and regulatory scrutiny
- Compliance considerations when partnering with digital health platforms

The discussion could focus on how companies can support innovation and patient access while maintaining appropriate compliance controls and oversight.

11:10 am Introductions, Discussions and Q&A

Amy Bensten, JD, *Head of Investigations for Americas, Ethics & Compliance, Takeda; Cambridge, MA*

Michele Guerino, MS, *Executive Director, Commercial Compliance Office, Human Health Ethics and Compliance, Merck; Former Senior Regional Business Director, Cubist Pharmaceuticals; Hopewell, NJ*

Edward "Ted" B. Diskant, JD, *Partner, McDermott Will & Schulte; Former Assistant US Attorney, Southern District of New York, US Department of Justice; New York, NY (Moderator)*

Mini Summit 21: Fair Market Value: Practical Strategies and Targeted Insights for Building Defensible FMV Frameworks

Building and deploying a consistent fair market value (FMV) program remains a cornerstone of compliance programs across the life sciences industry. Designed for professionals at all experience levels, this discussion will cover both foundational concepts and new challenges, including how to assess FMV for non-traditional stakeholders, ensure appropriate valuation for travel and related expenses, navigate some common pitfalls of operating in global markets, leverage data and new technology while maintaining defensibility, and more! Our expert panel of esteemed compliance professionals will share practical insights, lessons learned, and strategies to help organizations build adaptable, risk-based FMV frameworks that keep pace with innovation across the industry.

11:10 am Introductions, Discussions and Q&A

Abe Kassis, MBA, PhD, *Global Head Compliance and Legal Operations, Bausch + Lomb; Former Director of Corporate Compliance (Ethics & Compliance); Former Global Compliance, Director of Compliance, Takeda; New York, NY*

Yelena Ferreira, JD, *Head of Compliance and Assistant General Counsel, Pharmacosmos Therapeutics; Former Senior Director, Associate General Counsel, Pacira BioSciences; Morristown, NJ*

Eric Bolesh, *Chief Executive Officer, Cutting Edge Information; Research Triangle Park, NC (Moderator)*

Mini Summit 22: Navigating the Evolving US Privacy Landscape

As state privacy laws continue to multiply, understanding the common principles and requirements across these laws has never been more important. In this interactive session, our panelists will provide their insights and concerns regarding risks and compliance demands. Through real-world scenarios, attendees will learn how leading organizations prioritize compliance efforts and navigate the continuously evolving privacy landscape.

11:10 am Introductions, Discussions and Q&A

Simonne Brousseau, JD, *Associate, Faegre Drinker; Washington, DC*

Tom Hiney, CIPP/US, CIPM, JD, *Head, Digital Ethics & Compliance, US Business Unit, Takeda; Former Privacy Counsel, Blueprint Medicines; Boston, MA*

Courtney Lyles, *Manager, Privacy and Data Protection, Dovetail Consulting Group, Atlanta, GA*

Erin Wagenberg, CIPP/US, CIPP/E, CIPT, FIP, *Director, Dovetail Consulting Group; Former Deputy Privacy Officer, Deloitte Global; Atlanta, GA (Moderator)*

Mini Summit 23: Agentic Risk Management: Transforming Compliance Across Key Business Processes

As pharma compliance functions face growing pressure to do more with less, agentic AI offers a fundamentally different operating model — one where compliance intelligence is embedded directly into business workflows rather than applied as a downstream review layer. This session explores how agentic risk management is transforming the way compliance teams govern high-volume, rule-intensive business processes across the enterprise.

Key discussion points:

- How compliance functions can move from reactive, sample-based oversight to continuous, process-embedded risk management — and what that shift requires organizationally, technically, and culturally
- How to define which compliance controls belong in the workflow itself versus which require human escalation — and how that boundary differs by process type, risk level, and regulatory context
- What fit-for-purpose actually means when designing compliance controls for high-volume business processes — and why over-engineered

- controls are themselves a compliance risk when they drive workarounds
- How agentic compliance monitoring surfaces cross-functional risk patterns — spend concentration, repeat engagement, vendor dependency — that siloed process reviews and periodic audits consistently miss
- What audit-ready documentation looks like when compliance actions are taken by an AI agent rather than a human reviewer — and what regulators will expect to see
- How compliance teams make the case internally for embedding agentic oversight into business processes that commercial and medical stakeholders view as their own — and how to position compliance as an enabler rather than a gatekeeper

Attendees will leave with a practical framework for identifying which of their highest-volume compliance processes are most amenable to agentic transformation — and what governance infrastructure must be in place before that transformation begins.

11:10 am Introductions, Discussions and Q&A

Kevin Espinoza, *Chief Integrity & Compliance Officer, Indivior; Former Chief Integrity & Compliance Officer, Kaléo; Former Senior Vice President, Corporate Compliance, Boston Scientific; Richmond, VA*

Jeanille Gatta, MA, *Director, Compliance Business Partner, AstraZeneca, North America; Philadelphia, PA*

Stephanie Santana, MPH, PMP, *Associate Principal, ZS; New York, NY (Co-Moderator)*

Michael L. Shaw, JD, *Global Head of Compliance, Privacy and Risk, ZS; Former Vice President and Compliance Officer, GSK; Former Senior Counsel, Office of Inspector General, US Department of Health and Human Services; Princeton, NJ (Co-Moderator)*

12:00 pm Networking Luncheon in Exhibit Hall

NETWORKING LUNCHEON

(12:00 pm – 1:00 pm in Exhibit Hall)

OR OPTIONAL SMALL & MID-SIZED LIFE SCIENCE COMPANIES LUNCHEON:

12:00 pm – 1:00 pm Optional Luncheon Discussion:

Building Compliance from the Ground Up: A Roadmap for Small & Emerging Life Sciences Companies

Grab your box lunch and join an interactive discussion designed for emerging and smaller life sciences companies with limited or no existing compliance program infrastructure. This practical, risk-based session will help compliance leaders determine where to begin, which risks and program elements to prioritize, and how to build an effective compliance program as the organization grows.

The discussion will address questions such as:

- Which risks should be prioritized first?
- When should key compliance program elements and control be implemented?
- How do you build a roadmap that aligns with the company's stage of growth?
- How do you maximize limited resources while establishing an effective compliance program?



Discussion Facilitators:

Greg Demske, JD, *Partner, Goodwin Procter; Former Chief Counsel, Office of Inspector General, US Department of Health and Human Services; Washington, DC*



Jeffrey Kawalek, MBA, *Chief Compliance Officer, Zambon US; Former Deputy Chief Compliance Officer US, Jazz Pharmaceuticals; New York, NY (Former PCF Board Chair)*

PHARMACEUTICAL AND MEDICAL DEVICE CONGRESS

OPENING PLENARY SESSION

1:00 pm

Welcome and Introduction: PCF Board



Donna White, CCEP, Vice President, Compliance Officer, America Region, Chiesi Farmaceutici S.p.A.; Cary, NC (PCF Board Chair)

1:15 pm

C-Suite Congress Video Welcome



Albert Bourla, DVM, PhD, Chairman and Chief Executive Officer, Pfizer; Co-Chair, Partnership for New York City; Former Chair, Pharmaceutical Research and Manufacturers of America (PhRMA); Former President, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA); New York, NY

1:25 pm

Keynote Annual OIG Update



Mary E. Riordan, JD, Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector General, Department of Health and Human Services; Washington, DC

2:15 pm

Keynote US DOJ Criminal Division Update Fireside Chat



Jacob Foster, JD, Acting Chief, Health Care Fraud (HCF) Unit, Criminal Division, Fraud Section, US Department of Justice (DOJ); Former Trial Advocacy Project Deputy District Attorney, Los Angeles County District Attorney's Office; Washington, DC



Gary F. Giampetruzzi, JD, Partner & Global Chair Life Sciences, Paul Hastings; Former Vice President and Acting General Counsel, Head of Government Investigations, Pfizer; New York, NY (Moderator)

2:45 pm

Tech & Human-in-the-Loop Compliance (Why Human Judgment Matters More Than Ever)




Jason DiPietro, Senior Manager Compliance Analytics & Transparency Compliance, Lundbeck; Lake Zurich, IL



Rawan Fusisi, Head, Transparency and Third Party Compliance, Indivior; Former Transparency and Analytics Manager, Stryker; Washington, DC



Rajiv Mehrotra, MS, Senior Vice President, Data Science, HELIO; New York, NY



Marci Juneau, MBA, A Founding Partner, HELIO, Atlanta, GA (Moderator)

3:15 pm

Networking Break in Exhibit Hall

3:45 pm



The Next Generation of Compliance: Leveraging Data to Stay Ahead of Risk

David M. Blank, JD, Partner, Arnall, Golden, Gregory; Former Senior Counsel, US Department of Health and Human Services (HHS); Former Special Assistant US Attorney, US Attorney's Office Southern District of Mississippi; Washington, DC



Lindsey LaMoria Gavin, Senior Director, Deputy Compliance Officer, Lundbeck; Former Compliance Director, Meetings & Events International; Deerfield, IL



Al Park, Senior Compliance Officer, Global Monitoring, Auditing and Third-Party Risk Management, Global Ethics and Compliance, Jazz Pharmaceuticals; Former Global Program Effectiveness & Insights Leader, Worldwide Compliance & Business Ethics, Amgen; Phoenix, AZ



Robert Melillo, JD, Co-founder and Managing Director, G&M Health; Cocoa Beach, FL (Moderator)

4:15 pm

Integrated Risk Transformation in Pharma/Medical Device: From Compliance Burden to Strategic Advantage



Michael Reyes, Director, Risk & Regulatory Consulting, PwC; Former Analyst, Compliance Analytics, Edwards Lifesciences; Dallas, TX



Brian Riewerts, MPA, Partner, Pharmaceutical and Life Sciences Risk and Regulatory Leader, PwC; Washington, DC (Moderator)

4:45 pm

Annual Chief Compliance Officers Fireside Chat



Terra Buckley, JD, Chief Compliance & Ethics Officer, Bristol Myers Squibb; Former Chief Compliance Officer, LivaNova; Former Executive Director, Head, Business Advisory Center of Excellence, US Healthcare Compliance, Celgene; Summit, NJ



Christine Gordon, JD, Vice President, Risk, Assurance, & Compliance and Chief Compliance Officer, Americas; RAC Business Partner, Global SIS Division, Olympus Corporation of the Americas; Former Assistant District Attorney, Philadelphia District Attorney's Office; Bethlehem, PA



Melissa T. Lozner, JD, Senior Vice President, Chief Compliance Officer, Regeneron; Former Chief Compliance & Ethics Officer and Special Counsel, Rafael Holdings; Former Vice President, Head of Ethics, Risk & Compliance, Novartis; Tarrytown, NY (PCF Board Member)



Paul J. Silver, Principal, Life Sciences Regulatory, Compliance, and Legal Leader, Deloitte Consulting, Atlanta, GA (Moderator)

5:30 pm

ADJOURNMENT AND NETWORKING RECEPTION

PHARMACEUTICAL AND MEDICAL DEVICE ETHICS AND COMPLIANCE CONGRESS DAY 3

7:00 am Registration Opens: Breakfast Buffet


Attend the Invitation-only Chief Compliance Officer Roundtable — OR — Morning Mini Summits (see next page).

CHIEF COMPLIANCE OFFICER ROUNDTABLE

PCF-Sponsored, Exclusive Invitation-Only, Closed-Door session

7:00 am Breakfast will be served in the CCO Roundtable Meeting room

8:00 am CCO Roundtable Welcome and Introductions



Jill Dailey, JD, Vice President, Chief Compliance Officer, Oncology, Menarini Stemline; Former Vice President & Chief Compliance Officer, Incyte; Former Assistant General Counsel, Asia Pacific Compliance Lead, Pfizer; New York, NY (PCF Board Member)



Antitrust Admonition

Kristin Graham Koehler, JD, Managing Partner, DC Office & Executive Committee Member, Sidley Austin; Washington, DC

8:15 am Future of the Compliance Profession in an AI Driven Environment

AI is reshaping how compliance functions operate, how teams are structured, and what skills tomorrow's leaders must bring to the table. This panel brings together organizations of varying sizes to explore how AI is changing expectations, budgets, staffing models, and the competencies required for the next generation of compliance leadership.

The conversation will focus on practical realities: what companies are doing, where pressures are emerging, and how to prepare talent for a future where AI is embedded in every workflow.



Kevin Espinoza, Chief Integrity & Compliance Officer, Indivior; Former Chief Integrity & Compliance Officer, Kaléo; Former Senior Vice President, Corporate Compliance, Boston Scientific; Richmond, VA



Jim Gibney, Vice President, Global Compliance Operations, Corporate Compliance, Regeneron; Former Director, Worldwide Programs and US Investigations, Pfizer; Ridgewood, NJ



Rebekah Latchis, JD, Vice President, Risk Intelligence & Investigations, Office of Privacy, Integrity & Compliance, Medtronic; Former Corporate Responsibility Director, Bon Secours; Washington, DC



Natasha Trifun, JD, Head of Enterprise Compliance & Risk and Privacy, AstraZeneca; Former Head of Ethics and Compliance for EUCAN/ International, R&D, and Operations for Alexion AstraZeneca Rare Disease; Former Corporate Counsel, Brazil Compliance Officer, Pfizer; Boston, MA



Joy Dowdle, JD, Partner, Litigation Department, Paul Hastings and Co-Chair of the Houston Office; Houston, TX (Moderator)

9:00 am Executive Breakout by Company Size - Leveraging AI to Support Compliance Programs

Participants will dig into practical, real-world AI implementation, sharing how AI is actually being used inside their organizations—what's working, what's stalled, and where the biggest opportunities and risks are beginning to emerge.




Daniel Spicehandler, JD, Vice President Compliance, Commercial Divisions, Stryker; New York, NY (Pharma Congress Medical Device Executive Steering Committee)

9:40 am Networking Break

10:00 am Executive Breakout by Company Size - Building AI Ready Teams

Participants will share how they are upskilling their team to effectively leverage AI. Sharing how they're training current staff, recruiting future compliance talent, and building AI-ready skill sets across their programs.




Mona Peterson Rosow, JD, MPH, Former Vice President, Chief Risk, Ethics & Compliance Officer, Mozarc Medical; Former Compliance Officer, Medtronic; Minneapolis, MN (Pharma Congress Medical Device Executive Steering Committee)

10:40 am Board Oversight of Compliance: What Audit Firms Observe and What Regulators Require

As regulatory expectations intensify and AI accelerates business risk, Boards are reexamining what "good" compliance looks like—and whether their organizations are structured to deliver it. Yet many Boards still misunderstand the purpose, scope, and value of Compliance, creating gaps in oversight and weakening independence.

This session offers an inside look at what audit firms are seeing in board governance and cultural attitudes toward compliance. We will also explore the government's perspective on why robust compliance programs matter, and the oversight behaviors regulators expect Boards to demonstrate in the boardroom.



Katherine Buckley, MBA, Partner, Pharmaceutical and Life Sciences Risk & Regulatory Consulting Solutions, PwC; Philadelphia, PA



Saul B. Helman, MD, MBA, President and Managing Director, Epsilon Life Sciences; Chicago, IL



Tony Jordan, Partner, EY; Former Accounting Branch Chief - Boston District Office, US Securities and Exchange Commission; Boston, MA




Kenneth A. Polite, Jr, JD, Partner & Global Co-leader, White Collar Defense, Sidley Austin; Former Assistant Attorney General, Criminal Division, US Department of Justice; Washington, DC




Christie Camelio, Senior Vice President and Chief Compliance Officer, Insmed; Former Vice President & Deputy Global CCO, Celgene; Florham Park, NJ (PCF Board) (Moderator)

11:30 am

Open Forum: Opportunities for Benchmarking and Peer-driven Q&A. Bring your questions!



Jill Dailey, JD, Vice President, Chief Compliance Officer, Oncology, Menarini Stemline; Former Vice President & Chief Compliance Officer, Incyte; Former Assistant General Counsel, Asia Pacific Compliance Lead, Pfizer; New York, NY (PCF Board Member)




Mona Peterson Rosow, JD, MPH, Former Vice President, Chief Risk, Ethics & Compliance Officer, Mozarc Medical; Former Compliance Officer, Medtronic; Minneapolis, MN (Pharma Congress Medical Device Executive Steering Committee)



Daniel Spicehandler, JD, Vice President Compliance, Commercial Divisions, Stryker; New York, NY (Pharma Congress Medical Device Executive Steering Committee)

11:55 am

Wrap-up



Jill Dailey, JD, Vice President, Chief Compliance Officer, Oncology, Menarini Stemline; Former Vice President & Chief Compliance Officer, Incyte; Former Assistant General Counsel, Asia Pacific Compliance Lead, Pfizer; New York, NY (PCF Board Member)

Noon

Chief Compliance Officer Roundtable Adjournment

MORNING MINI SUMMITS: GROUP 5 (8:00 am - 8:50 am)

Mini Summit 24: Identifying and Managing Risk Associated with AI

8:00 am Introductions, Discussions and Q&A

Brent Boeckmann, MBA, *Strategic Advisor, Commercial Immunology Lead, US & Global Specialty Care, Sanofi; Boston, MA*

Jerel Smith, MSJ, *Chief Compliance Officer-Director Integrity & Compliance, Upsher-Smith; Former Director, Compliance Operations, Karyopharm Therapeutics; Former, Director, Biopharma Compliance, Pfizer; New York, NY*

Mohammad Ovais, *Founder & Board Member, qordata; Chief Executive Officer, Managing Director, Veraqor; Princeton, NJ (Moderator)*

Mini Summit 25: Transparency Reporting; Update on the Centers for Medicare and Medicaid Services Open Payments Program

8:00 am Introductions, Discussions and Q&A

Veronika Peleshchuk Fradlin, MPP, *Director, Transparency & Data Group, Centers for Medicare & Medicaid Services, US Department of Health and Human Services; Washington, DC*

Lisa M. Re, JD, *Partner, Life Sciences/Healthcare Regulatory Practice Group, Arnold & Porter; Former Assistant Inspector General for Legal Affairs, Office of Inspector General, US Department of Health and Human Services; Washington, DC (Moderator)*

Mini Summit 26: From Speak-Up to Proof: Turning DOJ and OIG Expectations into Defensible, AI-Enabled Compliance Operations

Regulators no longer view an effective compliance program as a set of policies on paper. They expect organizations to demonstrate, with evidence, that risks are being detected, escalated, investigated, and remediated in a consistent, measurable way. Recent DOJ guidance emphasizes the role of data, analytics, AI, and strong speak-up programs in supporting continuous risk detection.

The session will focus on practical, regulator-aligned approaches for moving from reactive case handling to proactive, evidence-based compliance management. Attendees will see how data, analytics, and AI can strengthen continuous risk detection, surface meaningful trends, and create the audit-ready records needed to demonstrate program effectiveness over time.

8:00 am Introductions, Discussions and Q&A

Allison Benkert, MBA, *Senior Director, Compliance Policies, Training & Investigations, Jazz Pharmaceuticals; Former Senior Director, Global Investigations, Pfizer; Former Head of Global Compliance Investigations, Seagen; Doylestown, PA*

Melissa (Missy) Kaschak, CPA, CFE, CISA, *GRC Operations, Olympus Corporations of the Americas; Center Valley, PA*

Aaron Lewis, MBA, *Director, Legal and Compliance Operations, Cordis; Former Director, Compliance Insights and Technologies, Cardinal Health; Miami Lakes, FL*

Brook Mishler, RN, MSN, *Global Director of Compliance Solutions, Life Sciences, Case IQ; Former Compliance Officer for the Americas, Cordis; Ontario, Canada (Co-Moderator)*

Shannon Walker, *Executive Vice President, Thought Leadership & Strategy, Case IQ; Founder and President, WhistleBlower Security; Ontario, Canada (Co-Moderator)*

Mini Summit 27: Manufacturer–Specialty Pharmacy Relationships: Managing Compliance Risk in Specialty and Rare Disease Commercial Models

Relationships between manufacturers and specialty pharmacies are foundational to modern specialty and rare disease commercial models, supporting patient access, adherence, and complex therapy management. At the same time, these arrangements operate in a legally sensitive space, raising recurring fraud and abuse questions around financial support, data sharing, service arrangements, and the degree of manufacturer involvement in pharmacy operations.

As manufacturers increasingly rely on specialty pharmacies to execute patient support and distribution strategies, compliance and legal teams are frequently asked to help define the appropriate level of collaboration with specialty pharmacies. This panel will examine the core compliance considerations that arise in manufacturer–specialty pharmacy relationships, focusing on practical risk identification, program design, and oversight approaches that reflect how these models function in the real world. Panelists will share perspectives on common friction points, recurring questions from internal stakeholders, and strategies for supporting patient access while maintaining appropriate compliance guardrails.

8:00 am Introductions, Discussions and Q&A

Elizabeth Conti, JD, *Senior Legal Counsel, Nestlé Health Science; Arlington, VA*

Aaron P. Maskery, CPA, CIA, *Senior Director, Compliance Operations, Mighty Therapeutics; Former Senior Director, Compliance, Karuna Therapeutics; Former Director, Compliance Auditing & Monitoring, Idorsia; Wilmington, DE*

Rakan F. Ghubej, JD, *Senior Director, Senior Corporate Counsel & Assistant Corporate Secretary, Kyowa Kirin; New York, NY*

Eliza L. Andonova, JD, *Partner, Global Regulatory, Hogan Lovells Cadwalader; Washington, DC (Moderator)*

Mini Summit 28: The Future of Compliance Monitoring: AI Agents, Risk Intelligence and Practical Adoption

With AI capabilities maturing rapidly, compliance leaders are evaluating how these technologies can move beyond experimentation and create measurable value within monitoring programs. Join us for a discussion on where AI is delivering value today within compliance monitoring programs, including a live demonstration of AI-enabled capabilities and practical examples. We will explore the evolving role of agentic AI relative to traditional analytics approaches, key cost considerations, governance implications, and lessons learned from organizations developing and deploying AI-enabled monitoring programs.

8:00 am Introductions, Discussions and Q&A

Kristiana Bankova, MS, *Senior Manager, Forensics, EY; New York, NY*

Libby M. Rosenberry, *Senior Manager, Forensic & Integrity Services, EY; Boston, MA*

8:50 am Transition Break

MORNING MINI SUMMITS: GROUP 6 (9:00 am - 9:50 am)

Mini Summit 29: Building the Compliance Operating Model for What's Next

As AI, automation, and advanced technologies reshape work, compliance can no longer rely on traditional operating models. This session explores how leading organizations are redesigning governance, talent, and oversight to manage new risks, enable innovation, and build a more connected, data-driven compliance function.

9:00 am Introductions, Discussions and Q&A

Monica Schroeter, CPA, CISA, VP, Head of Compliance, F2G; Former Head of Compliance Operations and Risk, LivaNova; Former Head of Compliance & Privacy, SK Life Sciences; Goshen, NY

Clarissa Crain, Managing Director, Life Sciences Regulatory, Compliance, and Legal Leader, Deloitte Consulting; Phoenixville, PA (Moderator)

Mini Summit 30: Leveraging AI for More Efficient and Effective Investigations

Legal, compliance, and investigations professionals are increasingly leveraging AI throughout the lifecycle of investigations. Not only do these tools drive cost and time efficiencies, but they also can help investigators get to the truth faster and with less business disruption. But at the same, deploying this technology can create risks if not done with appropriate care and planning. During this session we will:

- Offer practical and creative AI use cases (beyond the basics) throughout the investigation lifecycle, from intake to interviews to investigative output;
- Dig into legal issues presented by the use of AI in investigations, including how to avoid foot faults with respect to the attorney client privilege and attorney work product;
- Provide “watch-outs” or common mis-steps to avoid when leveraging AI tools in this context; and
- Consider how to leverage AI to not only respond to individual allegations, but also to use broader investigations data to identify trends

9:00 am Introductions, Discussions and Q&A

Mike D'Alessandro, CFE, CHC, CPA, Senior Manager, Forensics & Integrity Services, EY; Former Chief Ethics and Compliance Officer, ahma Rx; Iselin, NJ

Susana Franco, MBA, Director, Field Compliance and Investigations, Lundbeck; Former Director of Compliance Operations, Orthofix; Dallas, TX

Tracey Tran, Senior Manager, Forensic and Integrity Services, EY; New York, NY

Erin Brown Jones, MA, JD, Partner, Latham & Watkins; Washington, DC (Moderator)

Mini Summit 31: Compliance Considerations, Enforcements and Guidelines on Social Media Activities

9:00 am Introductions, Discussions and Q&A

Rosemary McKenna, JD, Executive Director, Regulatory Legal, Organon; Former Director, Regulatory-Legal, Merck; Philadelphia, PA

Nikki Reeves, JD, Partner, FDA & Life Sciences Practice Group, Co-Chair, Government Matters & Regulatory Practice Group, King & Spalding; Washington, DC (Moderator)

Mini Summit 32: Building a Compliance Roadmap: Practical Strategies for Scaling Compliance Programs

Building a compliance program is not a one-size-fits-all exercise. For life sciences companies navigating clinical/pre-commercial, commercialization, and growth stages, leaders must determine which risks require immediate attention, what elements are needed to address

them, and how to build a roadmap that aligns compliance priorities with business objectives.

In this panel discussion, experienced compliance leaders from companies at different maturity stages will share practical approaches to developing and implementing compliance roadmaps that appropriately address the risk at your organization, including:

- Identifying and prioritizing risks across different stages of organizational growth
- Determining what and when program components are needed and how they should evolve over time
- Leveraging existing resources, AI, and cross-functional partnerships to enhance compliance effectiveness
- Balancing competing priorities and resource constraints while maintaining a risk-based approach
- Real-world examples and lessons learned from building and maturing compliance programs

9:00 am Introductions, Discussions and Q&A

Geeta Kaveti, MHA, JD, Chief Compliance Officer & US General Counsel, Nyxoah; Former Vice President, Chief Compliance & Privacy Officer, Nevro; Former Division Counsel - Legal Regulatory & Compliance, Abbott; Vernon Hills, IL

Fabiana Morette-Lattea, LLM, LLB, Global Compliance Program Lead, Telix Pharmaceuticals; Former Associate Director, Compliance, Merck; Former Compliance Officer Europe and North America, Roche; Fishers, IN

Meghan Naas, MA, Corporate Compliance Officer, Innoviva Specialty Therapeutics; Former Head of Corporate Compliance, Adaptimmune; Former Senior Director, Global Operations and US Compliance Officer, Zai Lab; Waltham, MA

Eric Ortman, MBA, Senior Director, Legal Operations & Healthcare Compliance, 4D Molecular Therapeutics; Former Senior Director, Legal Operations, BeiGene; Former Director, Legal Operations, Ultragenyx Pharmaceutical; Walnut Creek, CA

Adam T. Oakley, Senior Director, Potomac River Partners; Washington, DC (Moderator)

Mini Summit 33: Fair Market Value in Flux: Navigating Complex Fee Arrangements, HCP & Patient Engagement, and Influencer Compensation Risks

Explore the evolving fair market value (FMV) landscape for healthcare professionals (HCPs), patients, and social media influencers with a focus on the unique market, regulatory, and compliance considerations that influence engagement strategies.

Key Details

- Examine the complexities of establishing FMV for HCPs and patients across markets with varying regulatory requirements, healthcare infrastructure, and economic conditions.
- Discuss challenges created by HCP scarcity, supply-and-demand dynamics, and market-specific restrictions that can affect engagement and compensation.
- Explore FMV considerations for social media influencers/digital opinion leaders, including the lack of standardized compensation benchmarks and platform variability.
- Review emerging compliance risks, including transparency and disclosure expectations, as well as heightened regulatory scrutiny over promotional versus educational content.

9:00 am Introductions, Discussions and Q&A

Sarah diFrancesca, JD, Head of US Compliance – Immunology/Dermatology, Incyte; Wilmington, DE

Ravneet Talwar, MBA, Senior Manager, Life Sciences & Healthcare Consulting Group, Paul Hastings; New York, NY

Laura A. Skinner, MBA, Managing Director, Life Sciences & Healthcare Consulting Group, Paul Hastings; Managing Director, Rare Disease Compliance Consortium; New York, NY (Moderator)

Mini Summit 34: Future Proofing the Compliance Function: Operating Models for an AI-Enabled World

As organizations navigate AI adoption, increasing regulatory expectations, and evolving business models, compliance leaders are reevaluating how their functions are structured and staffed. This session could explore emerging operating models, changing skill requirements, the impact of AI on compliance roles, and how organizations can position compliance teams for long-term success.

9:00 am Introductions, Discussions and Q&A

Craig B. Bleifer, JD, Partner, McGuire Woods; Former Corporate Vice President, General Counsel North America; Novo Nordisk; Former Senior Vice President, General Counsel & Secretary, Daiichi Sankyo; New York, NY

Brett Barlag, MBA, Senior Managing Director, Healthcare Risk Management and Advisory, FTI Consulting; New York, NY (Moderator)

9:50 am Networking Break in Exhibit Hall

MORNING MINI SUMMITS GROUP 7 (10:10 am – 11:00 am)

Mini Summit 35: Unstructured Data and Advanced Monitoring Strategies

- Updating your policies and procedures
- AI utilization and Governance
- Common Violations and areas for improvement
- Social Media Compliance
- Identifying Training Opportunities
- Email Monitoring
- Mobile Device Compliance

10:10 am Introductions, Discussions and Q&A

Ashley Blackwood, Manager, Compliance, MiMedx; Marietta, GA

Christina Woods, MHA, Partner, Pharmaceutical and Life Sciences Risk & Regulatory Consulting, PwC; New York, NY

Jeff Hyre, Vice President Sales, Healthcare and Life Sciences, Global Relay; Denver, CO (Moderator)

Mini Summit 36: Leading Practices for Managing Investigations Panel

When a report drops, the first 72 hours can define the outcome—this panel will show you how leading organizations respond with speed, rigor, and control. Hear practical, real-world approaches to critical steps in the investigation process, such as preserving evidence and privilege, aligning quickly with counsel and governance teams, reporting out to the organizations, and using various tools and approaches to get to the facts faster. You'll leave with actionable ideas that you can tailor to enhance your investigation practices.

10:10 am Introductions, Discussions and Q&A

John S. Rah, JD, Counsel and Head, Life Sciences Compliance Practice, Potter & Murdock; Potomac, MD

Olga Zinavenka, CPA, MBA, Head of Compliance Operations, Keenova; Former Executive Director, Head of Compliance Operations, Endo; Former Compliance Officer – Europe, Middle East and Africa; Paoli, PA

David Amendola, Director, Life Sciences, Resolution Economics; Former Global Compliance Risk, Evaluation & Management, ConvaTec; New York, NY (Moderator)

Mini Summit 37: From Makary to Overton: Reflections and Predictions on the FDA's Priorities

With a new FDA Commissioner announced in August and “micro” trends at the FDA continuing to shift every two to three months, this presentation tracks recent and rapidly evolving developments from peptides to tariffs. The discussion will evaluate where the agency stands today and what to watch considering the risks and opportunities likely to shape the life sciences industry in the coming months.

10:10 am Introductions, Discussions and Q&A

Dominick P. DiSabatino, JD, Partner, Sheppard Mullin Richter & Hampton; Washington, DC

Scott S. Liebman, JD, Partner, Chair of FDA Regulatory & Compliance, Co-Chair of Life Sciences Practice, Sheppard Mullin Richter & Hampton; New York, NY

Mini Summit 38: Compliance Considerations for Rare Disease Products

10:10 am Introductions, Discussions and Q&A

Cheryl Lee, MBA, Head of Compliance, Cycle Pharmaceuticals; Former Vice President, ECG Strategy and Execution; Former Vice President, Head of Compliance Worldwide Markets; New York, NY

Daniel S. Murdock, MBA, JD, Associate General Counsel, Sobi - Swedish Orphan Biovitrum AB (publ); Former Associate General Counsel - Life Sciences, McKinsey & Co; Former Assistant General Counsel, Indivior; Washington, DC

Craig B. Bleifer, JD, Partner, McGuire Woods; Former Corporate Vice President, General Counsel North America; Novo Nordisk; Former Senior Vice President, General Counsel & Secretary, Daiichi Sankyo; New York, NY (Moderator)

Mini Summit 39: From Oversight to Partnership: Strengthening Collaboration Between Compliance and the Business

Compliance and business functions share a common goal: enabling organizations to achieve their objectives responsibly and ethically. Yet too often, these functions operate in silos, creating friction, inefficiencies, and missed opportunities for collaboration. This panel discussion will explore how organizations can move from a traditional oversight model to a partnership approach that strengthens both business performance and risk management. Leaders from Compliance, Commercial Excellence, and Business Operations will share practical strategies for building trust, aligning objectives, leveraging data and analytics, and creating governance models that support informed decision-making. Attendees will leave with actionable insights for fostering stronger cross-functional partnerships and positioning Compliance as a strategic business partner that enables growth while maintaining appropriate oversight.

10:10 am Introductions, Discussions and Q&A

Jessica Constant, MS, Associate Director, Compliance & Business Controls – US Oncology, AstraZeneca; Former Global Compliance Business Partner, QIAGEN; Washington, DC

Edmund Greenidge JD, LL.M., CCEP, Senior Director, Compliance, Summit Therapeutics; Former R&D Ethics and Compliance Lead, Takeda; Former Vice President, Corporate Compliance, Aclaris Therapeutics; Menlo Park, CA

Angela Schwartz, JD, Senior Principal, Global Commercial Compliance Consulting Leader, IQVIA; Former Special Assistant District Attorney, Montgomery County District Attorney's Office; Philadelphia, PA (Moderator)

Mini Summit 40: Digital Ecosystem Considerations for Life Science Companies

Pharmaceutical companies have increasingly developed complex digital ecosystems that underly their patient support programs, provider outreach, digital marketing, data analytics, and AI initiatives. This session will review regulatory and practical considerations related to overseeing and safeguarding these digital ecosystems. During this session we will speak specifically regarding state and federal regulatory updates, heightened IT security expectations, and litigation and enforcement trends.

10:10 am Introductions, Discussions and Q&A

Siyka Bozadjieva-Galiova, JD, *Global Data and Privacy Senior Advisor, Medtronic; Minneapolis, MN*

Christine Moundas, JD, MPH, *Healthcare and Data Partner, Co-Head, Digital Health Initiative, Ropes & Gray; Former Analyst, Office of Inspector General, US Department of Health and Human Services; New York, NY (Moderator)*

11:00 am Transition Break

MORNING MINI SUMMITS GROUP 8 (11:10 am – 12:00 pm)

Mini Summit 41: Holistic, Ongoing Monitoring Case Studies in Compliance

11:10 am Introductions, Discussions and Q&A

Angela Rodin, MBA, *Principal, Global Ethics, KPMG; Former Vice President, Global Head of Investigations and Monitoring, GSK; Washington, DC (Co-Moderator)*

Jordan Seiferas, MS, *Principal, Life Sciences Data Modernization, KPMG US; Columbus, OH (Co-Moderator)*

Mini Summit 42: Emerging Commercial & Market Access Risk in Life Sciences: Navigating Innovation, Compliance, and Evolving Access Models

Review emerging compliance risks, including transparency and disclosure expectations, as well as heightened regulatory scrutiny over promotional versus educational content.

11:10 am Introductions, Discussions and Q&A

Sara Simon, JD, *Director of Compliance, IBSA USA; Former Director, US Health Care Compliance Certification Program, Center for Health & Pharmaceutical Law & Policy, Seton Hall University School of Law, Parsippany, NJ*

Anthony S. Greco, MBA, *Managing Director, Pharmaceutical & Life Sciences Advisory Services, PwC; Philadelphia, PA (Moderator)*

Mini Summit 43: Effectively Leveraging Post-Investigation Mitigation to Create a Narrative of Continuous Improvement

In many investigations the focus is often on intentional or negligent conduct of individuals. In the long run, however, the ability to draw lessons learned for your compliance program and to make programmatic improvements in areas like policies, controls, training, and communications provides more value. This panel will explore best practices in managing and tracking programmatic mitigation, when to keep outside counsel involved, when to turn to other SMEs, and ultimately how to incorporate this work into a narrative of continuous improvement. The 2024 DOJ Guidance on Compliance programs expects programs to focus on continuous improvement as a measure of effectiveness. Currently, a lot of focus is around the front end, the use of AI and analytics to identify instances of non-compliance or programmatic gaps, but equal attention is required on the back end, the pull through of mitigation efforts, to be able to tell a convincing story of actionable evaluation of effectiveness.

11:10 am Introductions, Discussions and Q&A

Aurélien Ercoli, LLM, PhD, *Partner, Life Sciences Practice Group, DLA Piper; Washington, DC*

Emily Treanor, JD, *Head of Global Investigations & Enterprise Risk Management, Alnylam Pharmaceuticals; Washington, DC*

Perri Pomper, JD, *Vice President, Compliance - Orthopaedics, Strategy & Education, Stryker; Former Vice President, Compliance & Legal Affairs, Clinical Genomics; Former Director, Ethics and Compliance Strategy & Education, Novo Nordisk; New York, NY*

Jeffrey Scott, JD, *Of Counsel, Life Sciences Practice Group, DLA Piper; Former Lead Compliance Counsel, Digital, Reporting, and Analytics, Pfizer; Philadelphia, PA (Moderator)*

Mini Summit 44: Data Analytics & Compliance Monitoring in an AI-Powered World

Structured and unstructured data is ubiquitous throughout our organizations, as is the opportunity – and the expectation – for compliance officers to actively engage with company data while using it to assess risk, monitor trends, and identify areas of potential concern.

With so many functions, so much data, so many possibilities, and so little time – where do you even begin? And what does “good” look like? How might the data we are collecting and analyzing be used to advance compliance programs and prevent or reduce revenue leakage, and how might the insights that data brings create concerns in its own right, such as concerns regarding violations of FDA or DEA regulations, or implications of the FCA and AKS? What tools work well, and how can they be used most effectively? What are the implications of this harnessing and monitoring data-driven information in investigations and litigation?

This session will discuss a range of data analytics and monitoring tools and techniques ranging from the simple to the complex, and will examine case studies to illuminate the life cycle of structured and unstructured data capture, analysis and ongoing monitoring – in addition to insights into how this same data can be analyzed in reactive scenarios.

12:10 pm Introductions, Discussions and Q&A

Ignatius Grande, JD, *Of Counsel, Winston Taylor; New York, NY*

Roberta Rima, MS, *Vice President, Global Compliance Audit, Monitoring & Analytics, Zimmer Biomet; Former Senior Director, Head of Third Party & Corporate Compliance Audit, Gilead; San Francisco, CA*

Stephanie M. Lewko, CFE, *Managing Director, Healthcare Disputes & Economics, Ankura; Washington, DC (Moderator)*

Mini Summit 45: Can Learning Data Reduce Risk? Using Measurement to Drive Defensible, Risk-Based Compliance Training

Regulators and auditors are no longer satisfied with completion rates and pass scores — they want documented evidence that training actually changed behavior and reduced risk. This session focuses specifically on compliance training programs: how to use assessment data, role-based segmentation, and adaptive learning pathways to build defensible proof of competency — not just activity. Attendees will leave with practical strategies for connecting training outcomes to behavioral indicators, right-sizing learning investments by risk level, and producing the audit-ready documentation that holds up under DOJ and OIG scrutiny.

Session continued next page

11:10 am Introductions, Discussions and Q&A

Adriana Davies, JSM, *Vice President Compliance and Privacy US and China, Smith+Nephew; Former Senior Program Director, Compliance Officer Surgical Innovations, Renal Care Solutions and Robotics, Medtronic; Former Regional Director Americas Ethics and Compliance & Group Corporate Programs, Terex Corporation; Jacksonville, FL*

A.D. Detrick, CPTM, *President, Founder, MetriVerse Analytics; Columbus, OH*

Jaya Saigal, *Senior Director, C&E Policy, Education, Communications, Culture of Integrity and Ombuds, Bristol Myers Squibb; Princeton, NJ*

Lily Zimmerman, *Learning Solution Architect, Tier1 Performance; Covington, KY (Moderator)*

Mini Summit 46: AI in Clinical Practice: Compliance, Governance & FDA Oversight

Regulation of AI in Clinical Practice, Including Clinical Decision Support Tools, Documentation, FDA Clearance Requirements, and Provider Credentialing Considerations

11:10 am Introductions, Discussions and Q&A

Julie K. Taitsman, MD, JD, *Managing Director, BDO, US; Former Chief Medical Officer, Office of Inspector General (OIG), US Department of Health & Human Services; Former Special Counsel for Health & Science, United States Senate Committee on Finance; Washington, DC*

Georgia Ravitz, JD, *Partner, FDA & Healthcare Regulatory, Orrick, Herrington & Sutcliffe; Washington, DC; (Moderator)*

12:00 pm Networking Luncheon**NETWORKING LUNCHEON****12:00 pm Networking Luncheon with Dessert and Coffee in the Exhibit Hall****LUNCHEON MINI SUMMITS GROUP 9 (12:10 pm – 1:00 pm)**

Pickup your box lunch in the Exhibit Hall and take it to the Luncheon Mini Summit room of your choice.

Mini Summit 47: Direct-to-Consumer (DTC) Models in the Pharmaceutical Space

- Discuss different DTC program models
- Provide an overview of recent OIG guidance and key laws and regulations impacting DTC programs
- Discuss compliance risk considerations related to execution of DTC programs with pharmacies, telehealth providers and other partners

12:10 pm Introductions, Discussions and Q&A

Kala Shankle, JD, *Vice President, Regulatory Affairs, Healthcare Distribution Alliance; President Elect, American Society for Pharmacy Law; Washington, DC*

Alison J. Fethke, JD, *Member of the Firm, Epstein Becker Green; Former Division Counsel, Legal Regulatory & Compliance, AbbVie; Chicago, IL (Moderator)*

Mini Summit 48: ROI of AI: Separating Value from Hype

AI has rapidly become a strategic priority across organizations, but the path from adoption to measurable value remains uneven. Many teams are piloting tools, investing in platforms, and exploring use cases, yet fewer can clearly articulate where AI is delivering sustained ROI.

This discussion will focus on separating high-value AI applications from hype-driven initiatives. Participants will share how their organizations are measuring success, what metrics they are using, which use cases are producing tangible impact, and where AI has fallen short of expectations.

- Difference definitions of ROI for AI
- Measuring Value in quantitative and qualitative terms
- Creating value while avoiding AI overload and fatigue
- Continued success with and without AI

12:10 pm Introductions, Discussions and Q&A

Stephanie Macholtz, JD, MBA, *Adjunct Faculty, Suffolk University Law School; Former Vice President, Healthcare Compliance, Organogenesis; Former Senior Director Global Compliance and Deputy General Counsel, Clinical Affairs, Apellis Pharmaceuticals; Cambridge, MA*

Omar S. Richardson, MBA, *Executive Director, Compliance, Shionogi; Former Compliance Officer, Grünenthal Group; New York, NY*

Kelly J. Tope, JD, MBA, *Head, Ethics & Business Integrity Governance, Operations & Risk Management-North America & Global Specialty Care, Sanofi; Former Head, USBU Ethics & Compliance Monitoring & Reporting Operations, Takeda; Boston, MA*

Katie Jacyna, *Chief Product Officer, HELIO; Denver, CO (Moderator)*

Mini Summit 49: Lean, Credible, Defensible: Compliance Programs That Work Without Big Budgets

This program focuses on building low cost, high impact compliance programs that regulators still view as credible and effective.

12:10 pm Introductions, Discussions and Q&A

Loren Becher, MPH, *Senior Director, Quality, Ethics, Compliance & Risk Enterprise Programs, Emergent BioSolutions; Former Director, Compliance Operations & Planning, AstraZeneca; Former Director, Chief of Staff & Enterprise Programs, Alexion Pharmaceuticals; Rye Brook, NY*

Julian Gabbard, JD, *Associate General Counsel, Meso Scale Diagnostics; Former Head of Legal and Compliance, Corporate Counsel, Kolon TissueGene; Former Senior Director, Arcellx; Washington, DC*

Elizabeth Weiss, JD, *Vice President, Chief Compliance & Privacy Officer, Invivyd; Former Head of Compliance for Americas & EMEA, Lupin; Former Senior Director, US Risk and Compliance, LEO Pharma; Former Assistant General Counsel, Compliance Lead, Global Health & Patient Access, Pfizer; Livingston, NJ*

Robert A. Wells, JD, *Health Care Regulatory Shareholder, Chair, Health Law and Government Solutions, Baker, Donelson, Bearman, Caldwell & Berkowitz; Baltimore, MD (Moderator)*

Mini Summit 50: A Look Under the Hood: Exploring PBM and Payer Arrangement Risks and Emerging Reporting Requirements

Channel partner arrangements are experiencing intensifying scrutiny as drug pricing and rebate strategies command the attention of federal and state legislators, regulators, enforcement authorities and the general public. Arrangements with Pharmacy Benefit Managers and Payers often reflect complex pricing and rebate arrangements that are frequently revised and represent significant value in the aggregate. As legislative and regulatory oversight expand and examination and reporting standards take effect, Compliance Officers are poised to actively evaluate these arrangements and their attendant components as part of a broader-swath risk management posture.

This session will discuss:

- An overview into the current federal and state political and legislative scrutiny applied to PBMs and their financial relationships with manufacturers
- An overview of Manufacturer, PBM and Prescription Drug Plan arrangements and flow of funds
- Auditing and monitoring strategies to bolster insights into manufacturer/channel partner arrangements
- Implications and considerations where arrangements overlap with drug pricing reforms
- Transparency reporting requirements for PBMs to report formulary, pricing, and summaries of their arrangements with manufacturers under the Consolidated Appropriations Act of 2026
- Impact on Market Access interactions and price negotiating tools in formulary placement efforts

8:00 am Introductions, Discussions and Q&A

Daryl Berke, JD, Assistant General Counsel, Specialty US Market Access Lead, Sanofi; Washington DC

Craig B. Bleifer, JD, Partner, McGuire Woods; Former Corporate Vice President, General Counsel North America; Novo Nordisk; Former Senior Vice President, General Counsel & Secretary, Daiichi Sankyo; New York, NY

Katherine C. Norris, MPA, Senior Managing Director, Life Sciences Compliance, Disputes & Economics, Ankura; Washington, DC (Moderator)

Mini Summit 51: Collaborating to Create Lasting Solutions During and After Monitoring or Investigations

12:10 pm Introductions, Discussions and Q&A

Katherine "Kate" Dyson, JD, Head of US Compliance, Alexion Pharmaceuticals; Former Head of Assurance, Alexion, AstraZeneca RDU; Former Senior Director, Neurology Compliance Business Partner; Alexion Pharmaceuticals; Boston, MA

Naveen Ganesh, MA, JD, Vice President, Global Head of Investigations, Ethics & Compliance, Takeda; Former Head of Investigations & Monitoring, North America & Global Specialty Care, Sanofi; Former Compliance Assurance & Investigations (Lead), Verily; Boston, MA

Kathryn Harris, JD, Head of US Compliance, Galderma; Former Senior Director, Global Compliance, Emergent BioSolutions; Former Compliance Business Partner (Market Access, Patient Services, and Strategic Accounts); Alexion Pharmaceuticals; Boston, MA

Audrey DeGuarde, MSJ, Vice President, General Manager, Commercial Compliance, MediSpend; Morristown, NJ (Moderator)

Mini Summit 52: Annual FDA Office of Prescription Drug Promotion Update

This session will explore the evolving compliance landscape for drug advertising and promotion from the perspective of Twyla Mosey, the Director of the Office of Prescription Drug Promotion ("OPDP") in the Center for Drug Evaluation and Research at FDA. The discussion will examine enforcement trends, including the surge in warning and untitled letters since the administration's "crackdown" on deceptive drug advertising announced in September 2025, as well as OPDP's current priorities and areas of focus. The discussion will provide practical guidance for companies on responding to OPDP enforcement letters, engaging constructively with OPDP, and strengthening compliance processes to mitigate advertising and promotion risk.

12:10 pm Introductions, Discussions and Q&A

Twyla Mosey, PharmD, RPh, Director, Office of Prescription Drug Promotion, US Food and Drug Administration, Washington, DC

Joshua (Josh) Oyster, JD, Partner, Life Sciences Regulatory & Compliance Practice, Ropes & Gray; Former Counsel, Humana; Washington, DC (Moderator)

1:00 pm Transition Break

CLOSING PLENARY SESSION

1:10 pm Welcome and Introduction: PCF Board

1:15 pm Keynote Annual DOJ Civil Division Update Fireside Chat



Brenna Jenny, JD, MPH, Deputy Assistant Attorney General, Commercial Litigation Branch, Civil Division, US Department of Justice; Former Principal Deputy General Counsel & Chief Legal Officer, Centers for Medicare & Medicaid Services, US Department of Health and Human Services; Washington, DC



Interviewed by:

Scott A. Memmott, JD, Partner, Morgan, Lewis & Bockius LLP; Former Special Assistant US Attorney, Criminal Division, US Attorney's Office, Eastern District of Virginia and Former Trial Attorney, US Department of Justice, Civil Division, US Department of Justice; Washington, DC

1:45 pm Investigations, Enforcement and Prosecutions Roundtable



Jennifer L. Bragg, JD, Partner, Latham & Watkins; Former Associate Chief Counsel for Enforcement, Office of Chief Counsel, US Food and Drug Administration; Washington, DC



Greg Demske, JD, Partner, Goodwin Procter; Former Chief Counsel, Office of Inspector General, US Department of Health and Human Services; Washington, DC



Preeya Noronha Pinto, JD, Partner, DLA Piper; Former Acting General Counsel, US Department of Health and Human Services; Washington, DC



Kip F. Ebel, MBA, Principal, Forensic & Integrity Services, EY; New York, NY (Moderator)


2:15 pm

**Updates from AdvaMed, BIO and PhRMA**

John Delacourt, JD, Deputy General Counsel, Biotechnology Innovation Organization; Former Chief Antitrust Counsel, Office of Policy Planning, US Federal Trade Commission; Washington, DC



Ida Nassar, JD, Vice President, Assistant General Counsel, Ethics & Compliance, AdvaMed; Former Senior Attorney, Office of Chief Counsel, US Drug Enforcement Administration; Washington, DC



Julie Ritchie Wagner, JD, Assistant General Counsel, PhRMA; Former Senior Counsel, Office of Counsel to the Inspector General, US Department of Health and Human Services; Washington, DC



Mark C. Scallon, MHA, Principal, Risk Advisory, Life Sciences Consulting, Compliance and Ethics Market Leader, Baker Tilly; Richmond, VA (Moderator)

2:45 pm

**Market Access in 2026 and Beyond: A Shifting Compliance Landscape**

Jill Dailey, JD, Vice President & Chief Compliance Officer, Oncology, Menarini Stemline; Former Vice President and Chief Compliance Officer, Incyte; Former Assistant General Counsel & Asia Pacific Compliance Lead, Pfizer; New York, NY (PCF Board Member)



Christian Scognamillo, JD, Associate General Counsel, US Market Access & Pricing, Abbvie; Former Senior Corporate Counsel, Market Access & Commercial Transactions, Exelixis; Former Senior Director, Legal, Access & Transactions, Alnylam, San Francisco, CA



Meena Datta, JD, Partner and Global Co-leader, Healthcare Practice, Sidley Austin; Chicago, IL (Moderator)

3:15 pm

Networking Break in Exhibit Hall

3:45 pm

**Burgeoning Compliance Risks**

Brian C. Barry, JD, Vice President, Chief Compliance Officer, Vertex Pharmaceuticals; Former Chief Compliance Officer & Compliance Counsel, EMD Serono; Boston, MA



Jennifer Dubas, JD, Chief Ethics and Compliance Officer, Jazz Pharmaceuticals; Former Senior Vice President, Chief Compliance Officer, Cencora; Former Senior Vice President, Chief Compliance Officer, AmerisourceBergen; Ambler, PA



Shannon Kelley, JD, Executive Vice President, Chief Legal Officer, Madrigal; Former Vice President, Head of Compliance; North America and Global Specialty Care GBU, Sanofi; Former Assistant US Attorney & Deputy Chief of Litigation, US Attorney's Office District of Massachusetts; Boston, MA



John S. Rah, JD, Counsel and Head, Life Sciences Compliance Practice, Potter & Murdock; Potomac, MD



Yogesh Bahl, MBA, Partner and Practice Leader, Resolution Life Sciences and Healthcare; Chief Financial Officer and Head of Investor Relations, IACTA Pharmaceuticals; New York, NY (Moderator)

4:15 pm

**AI and the Evolving Compliance Function**

Peter Brensilver, JD, MPH, Senior Vice President, Chief Global Commercial Compliance & Risk Counsel, Pfizer; New York, NY



Jennifer Dubas, JD, Chief Ethics and Compliance Officer, Jazz Pharmaceuticals; Former Senior Vice President, Chief Compliance Officer, Cencora; Former Senior Vice President, Chief Compliance Officer, AmerisourceBergen; Ambler, PA



Rebekah Latchis, JD, Vice President, Risk Intelligence & Investigations, Office of Privacy, Integrity & Compliance, Medtronic; Former Corporate Responsibility Director, Bon Secours; Washington, DC



Neeraj Gupta, MBA, President, Chief Technology Officer, Cresen Solutions; Chester Springs, PA (Moderator)

4:45 pm

**Managing Risk in Unsettled Times**

Deborah A. Curtis, JD, Partner & Co-Chair, White Collar Defense & Investigations Practice, Arnold & Porter; Former Deputy General Counsel, Central Intelligence Agency; Former Deputy Chief, Counterespionage Section, National Security Division, US Department of Justice; Former Deputy Chief, National Security Section, District of Columbia US Attorneys' Office; Washington, DC



Ambassador Barbara A. Leaf, JD, Senior International Policy Advisor, Arnold & Porter; Former Special Assistant to the President and Senior Director for the Middle East and North Africa; Former Assistant Secretary of State for Near Eastern Affairs, and Former US Ambassador to the United Arab Emirates, US State Department; Washington, DC



Forrest Deegan, JD, Principal Consultant, Spark Compliance Consulting, a Diligent brand; Co-Chair, Corporate Compliance & Ethics Subcommittee, Business Law Section, American Bar Association; Former Chief Ethics and Compliance Officer, Abercrombie & Fitch and Victoria's Secret; Columbus, OH (Moderator)

5:15 pm

ADJOURNMENT

PHARMACEUTICAL AND MEDICAL DEVICE ETHICS AND COMPLIANCE CONGRESS DAY 4

PCF INDUSTRY-ONLY COMPLIANCE BEST PRACTICES THINK TANK

(Industry-only Session for Pharmaceutical and Medical Device Company Ethics and Compliance Professionals and In-house Counsel only. Hosted by PCF)

8:00 am

Welcome and Introductions



Daryl Kreml, JD, Head, Ethics & Compliance, Global Oncology, Takeda; Former Senior Vice President, Chief Enterprise, Risk & Compliance Officer, Sage; Former US Compliance & Global Program Management, Biogen; Boston Scientific; Boston, MA (PCF Board Member)



Antitrust Admonition

Brian A. Bohnenkamp, MHA, JD, Partner, FDA and Life Sciences, King & Spalding; Washington, DC

8:10 am

Inside the New DOJ Initiative: The Rising Importance of Data Miners

The DOJ has added a powerful new tool to its enforcement toolbox: Data Miners. Under its new initiative, the Department is partnering with select data-miner relators who can sift massive public datasets to uncover statistical anomalies, hidden patterns, and potential False Claims Act violations. We'll break down what this initiative means for compliance teams, how data-driven allegations may originate and evolve, and the practical steps organizations should take now to strengthen monitoring, documentation, and response readiness.

This session features a panel moderated by Mark Jensen, a 30-year defense-side veteran of pharmaceutical investigations and FCA litigation, with insights from economist Andrée-Anne Fournier from the Analysis Group, who brings extensive expertise in data analysis and has paired with Mark to develop data-driven defenses in life sciences matters for over a decade, and with further perspective from Corey Amundson, a former Acting U.S. Attorney, Section Chief in DOJ's Criminal Division, head of DOJ's internal affairs, and longtime Assistant U.S. Attorney specializing in healthcare fraud and other white-collar crimes. In these roles, Corey led multiple crisis-response efforts and developed proactive enforcement initiatives aligned with DOJ priorities—including one of the nation's first healthcare fraud strike forces, the Criminal Division Corporate Whistleblower Awards Pilot Program, and a financial-fraud task force built around data-mining analytics.



Featuring:

Corey R. Amundson, JD, Partner, Special Matters & Government Investigations Practice Group, King & Spalding; Former Head, Public Integrity Section, US Department of Justice; Former Acting US Attorney, Middle District of Louisiana; Washington, DC



Andrée-Anne Fournier, MA, Managing Principal, Analysis Group; Brookline, MA



Mark A. Jensen, JD, Co-Chair & Partner, Special Matters & Government Investigations, King & Spalding; Washington, DC

8:45 am

Wins & Losses in the Early Days of AI – Audience Discussion Session

AI has entered compliance workflows with remarkable speed—and with uneven results. Some teams are already seeing meaningful efficiency gains, while others are wrestling with adoption challenges, accuracy concerns, governance gaps, or cultural resistance.

We'll discuss early wins, early failures, and the real-world lessons learned from attendees implementing AI in compliance programs. This is a candid, practical discussion about what's working, what isn't, and how organizations are navigating the realities of building AI-enabled compliance functions. Come prepared to share!



Anisa Dhalla, Vice President, Chief Ethics and Compliance Officer; Global Head, Ethics and Compliance, UCB; Atlanta, GA (PCF Board Member)



Daryl Kreml, JD, Head, Ethics & Compliance, Global Oncology, Takeda; Former Senior Vice President, Chief Enterprise, Risk & Compliance Officer, Sage; Former US Compliance & Global Program Management, Biogen; Boston Scientific; Boston, MA (PCF Board Member)




Tara Shewchuk, JD, LLM, Senior Vice President, Chief Privacy, Integrity & Compliance Officer, Medtronic; Minneapolis, MN (Pharma Congress Medical Device Executive Committee)

9:15 am

Benchmarking and Q&A Forum

Opportunity for polling, asking questions and benchmark against peers for valuable insights—Come prepared with questions!



Anisa Dhalla, Vice President, Chief Ethics and Compliance Officer; Global Head, Ethics and Compliance, UCB; Atlanta, GA (PCF Board Member)



Daryl Kreml, JD, Head, Ethics & Compliance, Global Oncology, Takeda; Former Senior Vice President, Chief Enterprise, Risk & Compliance Officer, Sage; Former US Compliance & Global Program Management, Biogen; Boston Scientific; Boston, MA (PCF Board Member)



Tara Shewchuk, JD, LLM, Senior Vice President, Chief Privacy, Integrity & Compliance Officer, Medtronic; Minneapolis, MN (Pharma Congress Medical Device Executive Committee)

10:00 am

Networking Break

10:20 am

Customer-Centric Complexity: Meeting Customer Needs While Balancing Field Pressures

Customer expectations and field realities are shifting faster than traditional governance models can absorb. Field teams are navigating mounting office restrictions, expanding reimbursement responsibilities, role overlapping, emerging roles, and an escalating need for data—all within the constraints of firewalls and privacy requirements.


Panelists will discuss how organizations can modernize governance to keep pace—enabling coordinated, compliant, and customer-centric engagement amid accelerating change.



Michelle Murphy, Executive Director, Compliance, Regeneron; New York, NY



Denis Jacob, Ethics & Compliance Americas Regional Leader, Solvntum; Former Ethics & Compliance Business Partner, Orthopedics, Henry Schein; Former Head of Compliance Audit and Investigations, GE; New York, NY



Laura E. Heyduk, Vice President, Head of Global Compliance, KalVista Pharmaceuticals; Former Head of US Compliance, Biogen; Former Compliance Director, Healthcare Compliance, Insulet Corporation; Cambridge, MA (Moderator)

11:00 am

Breakouts by Company Size

Topics Include:

- Cross-Functional Account Planning – roles, permissible topics, frequency and guardrails

11:30 am

Last Minute Questions – Wrap Up – Adjournment

Anisa Dhalla, Vice President, Chief Ethics and Compliance Officer; Global Head, Ethics and Compliance, UCB; Atlanta, GA (PCF Board Member)

Noon

CONGRESS ADJOURNMENT